


WHAT IS CLAIMED IS:

1. A therapeutic agent for hepatitis C, which comprises a fused ring compound of the following formula [I] or a pharmaceutically acceptable salt thereof as an active ingredient:



wherein

a broken line is a single bond or a double bond,

G^1 is $C(-R^1)$ or a nitrogen atom,

G^2 is $C(-R^2)$ or a nitrogen atom,

G^3 is $C(-R^3)$ or a nitrogen atom,

G^4 is $C(-R^4)$ or a nitrogen atom,

G^5 , G^6 , G^8 and G^9 are each independently a carbon atom or a nitrogen atom,

G^7 is $C(-R^7)$, an oxygen atom, a sulfur atom, or a nitrogen atom optionally substituted by R^8 ,

wherein R^1 , R^2 , R^3 and R^4 are each independently,

(1) hydrogen atom,

(2) C_{1-6} alkanoyl,

(3) carboxyl,

(4) cyano,

(5) nitro,

(6) C_{1-6} alkyl optionally substituted by 1 to 3

substituent(s) selected from the following group A,

group A; halogen atom, hydroxyl group, carboxyl, amino,

C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkoxy, C_{1-6}

alkoxycarbonyl and C_{1-6} alkylamino,

(7) $-COOR^{a1}$

wherein R^{a1} is optionally substituted C_{1-6} alkyl (as defined above), C_{6-14} aryl C_{1-6} alkyl optionally

substituted by 1 to 5 substituent(s) selected from the following group B or glucuronic acid residue,

group B; halogen atom, cyano, nitro, C_{1-6} alkyl,

halogenated C₁₋₆ alkyl, C₁₋₆ alkanoyl,
 -(CH₂)_r-COOR^{b1}, -(CH₂)_r-CONR^{b1}R^{b2}, -(CH₂)_r-NR^{b1}R^{b2},
 -(CH₂)_r-NR^{b1}-COR^{b2}, -(CH₂)_r-NHSO₂R^{b1}, -(CH₂)_r-OR^{b1},
 -(CH₂)_r-SR^{b1}, -(CH₂)_r-SO₂R^{b1} and -(CH₂)_r-SO₂NR^{b1}R^{b2}
 wherein R^{b1} and R^{b2} are each independently
 hydrogen atom or C₁₋₆ alkyl and r is 0 or an
 integer of 1 to 6,

(8) -CONR^{a2}R^{a3}

wherein R^{a2} and R^{a3} are each independently hydrogen atom,
 C₁₋₆ alkoxy or optionally substituted C₁₋₆ alkyl (as
 defined above),

(9) -C(=NR^{a4})NH₂

wherein R^{a4} is hydrogen atom or hydroxyl group,

(10) -NHR^{a5}

wherein R^{a5} is hydrogen atom, C₁₋₆ alkanoyl or C₁₋₆
 alkylsulfonyl,

(11) -OR^{a6}

wherein R^{a6} is hydrogen atom or optionally substituted
 C₁₋₆ alkyl (as defined above),

(12) -SO₂R^{a7}

wherein R^{a7} is hydroxyl group, amino, C₁₋₆ alkyl or C₁₋₆
 alkylamino,

(13) -P(=O)(OR^{a31})₂

wherein R^{a31} is hydrogen atom, optionally substituted C₁₋₆
 alkyl (as defined above) or C₆₋₁₄ aryl C₁₋₆ alkyl
 optionally substituted by 1 to 5 substituent(s)
 selected from the above group B

or

(14) heterocyclic group having 1 to 4 heteroatom(s)

selected from an oxygen atom, a nitrogen atom and a
 sulfur atom, and


R⁷ and R⁸ are each hydrogen atom or optionally substituted
 C₁₋₆ alkyl (as defined above),

ring Cy is

(1) C₃₋₈ cycloalkyl optionally substituted by 1 to 5

substituent(s) selected from the following group C,
 group C; hydroxyl group, halogen atom, C₁₋₆ alkyl and
 C₁₋₆ alkoxy,

- (2) C₃₋₈ cycloalkenyl optionally substituted by 1 to 5
 substituent(s) selected from the above group C, or
 (3)



5 wherein u and v are each independently an integer
 of 1 to 3,

ring A is

- (1) C₆₋₁₄ aryl,
 (2) C₃₋₈ cycloalkyl,
 10 (3) C₃₋₈ cycloalkenyl or
 (4) heterocyclic group having 1 to 4 heteroatom(s)
 selected from an oxygen atom, a nitrogen atom and a
 sulfur atom,

R⁵ and R⁶ are each independently

- 15 (1) hydrogen atom,
 (2) halogen atom,
 (3) optionally substituted C₁₋₆ alkyl (as defined above) or
 (4) -OR^{a8}

20 wherein R^{a8} is hydrogen atom, C₁₋₆ alkyl or C₆₋₁₄ aryl C₁₋₆
 alkyl, and

X is

- (1) hydrogen atom,
 (2) halogen atom,
 (3) cyano,
 25 (4) nitro,
 (5) amino, C₁₋₆ alkanoylamino,
 (6) C₁₋₆ alkylsulfonyl,
 (7) optionally substituted C₁₋₆ alkyl (as defined above),
 (8) C₂₋₆ alkenyl optionally substituted by 1 to 3
 30 substituent(s) selected from the above group A,
 (9) -COOR^{a9}

wherein R^{a9} is hydrogen atom or C₁₋₆ alkyl,

- (10) -CONH-(CH₂)₁-R^{a10}


wherein R^{a10} is optionally substituted C_{1-6} alkyl (as defined above), C_{1-6} alkoxy carbonyl or C_{1-6} alkanoylamino and l is 0 or an integer of 1 to 6,

(11) $-OR^{a11}$

wherein R^{a11} is hydrogen atom or optionally substituted C_{1-6} alkyl (as defined above)

or

(12)



wherein

ring B is

(1') C_{6-14} aryl,

(2') C_{3-8} cycloalkyl or

(3') heterocyclic group (as defined above),

each Z is independently

(1') a group selected from the following group D,

(2') C_{6-14} aryl optionally substituted by 1 to 5 substituent(s) selected from the following group D,

(3') C_{3-8} cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from the following group D,

(4') C_{6-14} aryl C_{1-6} alkyl optionally substituted by 1 to 5 substituent(s) selected from the following group D,

(5') heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the following group D,

wherein the heterocyclic group has 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom, or

(6') heterocycle C_{1-6} alkyl optionally substituted by 1 to 5 substituent(s) selected from the following group D,

wherein the heterocycle C_{1-6} alkyl is C_{1-6} alkyl substituted by heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the group D, as defined above,

group D:

- (a) hydrogen atom,
(b) halogen atom,
(c) cyano,
(d) nitro,
5 (e) optionally substituted C₁₋₆ alkyl (as defined above),
(f) $-(CH_2)_t-COR^{a18}$,
(hereinafter each t means independently 0 or an integer of 1 to 6),
10 wherein R^{a18} is
(1") optionally substituted C₁₋₆ alkyl (as defined above),
(2") C₆₋₁₄ aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B or
15 (3") heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B
wherein the heterocyclic group has 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom,
20 (g) $-(CH_2)_t-COOR^{a19}$
wherein R^{a19} is hydrogen atom, optionally substituted C₁₋₆ alkyl (as defined above) or C₆₋₁₄ aryl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group
25 B,
(h) $-(CH_2)_t-CONR^{a27}R^{a28}$
wherein R^{a27} and R^{a28} are each independently,
30 (1") hydrogen atom,
(2") optionally substituted C₁₋₆ alkyl (as defined above),
(3") C₆₋₁₄ aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
35 (4") C₆₋₁₄ aryl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

- (5") heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (6") heterocycle C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- wherein the heterocycle C₁₋₆ alkyl is C₁₋₆ alkyl substituted by heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B, as defined above,
- (7") C₃₋₈ cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (8") C₃₋₈ cycloalkyl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (9") hydroxyl group or
- (10") C₁₋₆ alkoxy,
- (i) $-(CH_2)_t-C(=NR^{a33})NH_2$
 wherein R^{a33} is hydrogen atom, C₁₋₆ alkyl, hydroxyl group or C₁₋₆ alkoxy,
- (j) $-(CH_2)_t-OR^{a20}$
 wherein R^{a20} is
- (1") hydrogen atom,
- (2") optionally substituted C₁₋₆ alkyl (as defined above),
- (3") optionally substituted C₂₋₆ alkenyl (as defined above),
- (4") C₂₋₆ alkynyl optionally substituted by 1 to 3 substituent(s) selected from the above group A,
- (5") C₆₋₁₄ aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (6") C₆₋₁₄ aryl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (7") heterocyclic group optionally substituted

- by 1 to 5 substituent(s) selected from the above group B,
- (8") heterocycle C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (9") C₃₋₈ cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B, or
- (10") C₃₋₈ cycloalkyl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (k) $-(CH_2)_t-O-(CH_2)_p-COR^{a21}$
 wherein R^{a21} is amino, C₁₋₆ alkylamino or heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B, and p is 0 or an integer of 1 to 6,
- (l) $-(CH_2)_t-NR^{a22}R^{a23}$
 wherein R^{a22} and R^{a23} are each independently
- (1") hydrogen atom,
- (2") optionally substituted C₁₋₆ alkyl (as defined above),
- (3") C₆₋₁₄ aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (4") C₆₋₁₄ aryl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (5") heterocycle C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B or
- (6") heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (m) $-(CH_2)_t-NR^{a29}CO-R^{a24}$
 wherein R^{a29} is hydrogen atom, C₁₋₆ alkyl or C₁₋₆ alkanoyl, and R^{a24} is
- (1") amino,
- (2") C₁₋₆ alkylamino,

(3'') optionally substituted C₁₋₆ alkyl (as defined above),

(4'') C₆₋₁₄ aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(5'') heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B or

(6'') heterocycle C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(n) $-(CH_2)_t-NR^{a29}SO_2-R^{a25}$

wherein R^{a29} is as defined above, and

R^{a25} is hydrogen atom, optionally

substituted C₁₋₆ alkyl (as defined above),

C₆₋₁₄ aryl optionally substituted by 1 to 5

substituent(s) selected from the above group

B or heterocyclic group optionally

substituted by 1 to 5 substituent(s) selected

from the above group B,

(o) $-(CH_2)_t-S(O)_q-R^{a25}$

wherein R^{a25} is as defined above, and q is 0, 1 or 2,

(p) $-(CH_2)_t-SO_2-NHR^{a26}$

wherein R^{a26} is hydrogen atom, optionally

substituted C₁₋₆ alkyl (as defined above),

C₆₋₁₄ aryl optionally substituted by 1 to 5

substituent(s) selected from the above group

B or heterocyclic group optionally

substituted by 1 to 5 substituent(s) selected

from the above group B,

and

(q) heterocyclic group having 1 to 4 heteroatom(s)

selected from an oxygen atom, a nitrogen atom

and a sulfur atom, and

w is an integer of 1 to 3, and

Y is

(1') a single bond,

(2') C₁₋₆ alkylene,
(3') C₂₋₆ alkenylene,
(4') -(CH₂)_m-O-(CH₂)_n-,
(hereinafter m and n are each independently 0
or an integer of 1 to 6),

(5') -CO-,
(6') -CO₂-(CH₂)_n-,
(7') -CONH-(CH₂)_n-NH-,
(8') -NHCO₂-,

(9') -NHCONH-,
(10') -O-(CH₂)_n-CO-,
(11') -O-(CH₂)_n-O-,
(12') -SO₂-,

(13') -(CH₂)_m-NR^{a12}-(CH₂)_n-

wherein R^{a12} is

(1") hydrogen atom,
(2") optionally substituted C₁₋₆ alkyl (as
defined above),
(3") C₆₋₁₄ aryl C₁₋₆ alkyl optionally
substituted by 1 to 5 substituent(s)
selected from the above group B,
(4") C₆₋₁₄ aryl optionally substituted by 1 to
5 substituent(s) selected from the above
group B,
(5") -COR^{b5}

wherein R^{b5} is hydrogen atom, optionally
substituted C₁₋₆ alkyl (as defined above),
C₆₋₁₄ aryl optionally substituted by 1 to
5 substituent(s) selected from the above
group B or C₆₋₁₄ aryl C₁₋₆ alkyl optionally
substituted by 1 to 5 substituent(s)
selected from the above group B,

(6") -COOR^{b5} (R^{b5} is as defined above) or
(7") -SO₂R^{b5} (R^{b5} is as defined above),

(14') -NR^{a12}CO- (R^{a12} is as defined above),
(15') -CONR^{a13}-(CH₂)_n-

wherein R^{a13} is hydrogen atom, optionally
substituted C₁₋₆ alkyl (as defined above) or

C₆₋₁₄ aryl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(16') -CONH-CHR^{a14}-

wherein R^{a14} is C₆₋₁₄ aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(17') -O-(CH₂)_m-CR^{a15}R^{a16}-(CH₂)_n-

wherein R^{a15} and R^{a16} are each independently

(1") hydrogen atom,

(2") carboxyl,

(3") C₁₋₆ alkyl,


(4") -OR^{b6}

wherein R^{b6} is C₁₋₆ alkyl or C₆₋₁₄ aryl C₁₋₆ alkyl, or

(5") -NHR^{b7}

wherein R^{b7} is hydrogen atom, C₁₋₆ alkyl, C₁₋₆ alkanoyl or C₆₋₁₄ aryl C₁₋₆ alkyloxycarbonyl, or R^{a15} is optionally

(6")



wherein n', ring B', Z' and w' are the same as the above-mentioned n, ring B, Z and w, respectively, and may be the same as or different from the respective counterparts,

(18') -(CH₂)_n-NR^{a12}-CHR^{a15}- (R^{a12} and R^{a15} are each as defined above),

(19') -NR^{a17}SO₂-

wherein R^{a17} is hydrogen atom or C₁₋₆ alkyl,

(20') -S(O)_e-(CH₂)_m-CR^{a15}R^{a16}-(CH₂)_n- (e is 0, 1 or 2, R^{a15} and R^{a16} are each as defined above),

or


(21') -(CH₂)_m-CR^{a15}R^{a16}-(CH₂)_n- (R^{a15} and R^{a16} are each as defined above).

2. The therapeutic agent of claim 1, wherein 1 to 4 of the G¹, G², G³, G⁴, G⁵, G⁶, G⁷, G⁸ and G⁹ is(are) a nitrogen atom.

3. The therapeutic agent of claim 2, wherein G^2 is $C(-R^2)$ and G^6 is a carbon atom.


5 4. The therapeutic agent of claim 2, wherein G^5 is a nitrogen atom.

5. The therapeutic agent of claim 1, wherein, in formula [I], the moiety




10

is a fused ring selected from




6. The therapeutic agent of claim 5, wherein, in formula [I], the moiety




5

is a fused ring selected from




7. The therapeutic agent of claim 6, which comprises a fused ring compound of the following formula [I-1]



5


wherein each symbol is as defined in claim 1,
or a pharmaceutically acceptable salt thereof as an active
ingredient.

10 8. The therapeutic agent of claim 6, which comprises a fused ring compound of the following formula [I-2]



wherein each symbol is as defined in claim 1,
or a pharmaceutically acceptable salt thereof as an active
15 ingredient.


9. The therapeutic agent of claim 6, which comprises a fused ring compound of the following formula [I-3]



wherein each symbol is as defined in claim 1,
or a pharmaceutically acceptable salt thereof as an active
ingredient.

5


10. The therapeutic agent of claim 6, which comprises a fused
ring compound of the following formula [I-4]



wherein each symbol is as defined in claim 1,

10 or a pharmaceutically acceptable salt thereof as an active
ingredient.

11. The therapeutic agent of claim 1, wherein at least one of R¹,
R², R³ and R⁴ is carboxyl, -COOR^{a1}, -CONR^{a2}R^{a3}, -SO₂R^{a7} (wherein R^{a1},
15 R^{a2}, R^{a3} and R^{a7} are as defined in claim 1),




12. The therapeutic agent of claim 11, wherein at least one of R¹,
R², R³ and R⁴ is carboxyl, -COOR^{a1}, -CONR^{a2}R^{a3} or -SO₂R^{a7} wherein R^{a1},
20 R^{a2}, R^{a3} and R^{a7} are as defined in claim 1.

13. The therapeutic agent of claim 1, wherein at least one of R^1 , R^2 , R^3 and R^4 is $-\text{COOR}^{a1}$ wherein R^{a1} is glucuronic acid residue.

14. The therapeutic agent of claim 1, wherein at least one of R^1 , R^2 , R^3 and R^4 is heterocyclic group having 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom.

15. The therapeutic agent of claim 1, wherein the ring Cy is cyclopentyl, cyclohexyl, cycloheptyl, tetrahydrothiopyranyl or piperidino.

16. The therapeutic agent of claim 1, wherein the ring Cy is



wherein each symbol is as defined in claim 1.

15

17. The therapeutic agent of claim 1, wherein the ring A is C_{6-14} aryl.


18. The therapeutic agent of claim 1, wherein at least one substituent optionally substituted by group A is a substituent substituted by C_{1-6} alkoxy C_{1-6} alkoxy.

19. The therapeutic agent of claim 1, wherein the Y is $-(\text{CH}_2)_m-\text{CR}^{a15}\text{R}^{a16}-(\text{CH}_2)_n-$ wherein each symbol is as defined in claim 1.

25

20. The therapeutic agent of claim 1, wherein at least one group represented by Z is heterocycle C_{1-6} alkyl optionally substituted by 1 to 5 substituent(s) selected from the group D.


21. The therapeutic agent of claim 1, wherein at least one group represented by Z is a heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the group D, wherein said heterocyclic group is selected from the following groups:



5 wherein E^1 is an oxygen atom, a sulfur atom or $N(-R^{a35})$, E^2 is an oxygen atom, CH_2 or $N(-R^{a35})$, E^3 is an oxygen atom or a sulfur atom, wherein each R^{a35} is independently hydrogen atom or C_{1-6} alkyl, f is an integer of 1 to 3, and h and h' are the same or different and each is an integer of 1 to 3.

10 22. The therapeutic agent of claim 21, wherein at least one group represented by Z is heterocyclic group optionally substituted by

1 to 5 substituent(s) selected from the group D wherein said heterocyclic group is selected from the following groups:



5 wherein each symbol is as defined in claim 21.

23. The therapeutic agent of claim 1, wherein at least one group represented by group D is $-(CH_2)_t-CONR^{a27}R^{a28}$ wherein each symbol is as defined in claim 1, and at least one of R^{a27} and R^{a28} is C_{1-6} alkoxy.

10

24. The therapeutic agent of claim 1, wherein at least one group represented by group D is $-(CH_2)_t-C(=NR^{a33})NH_2$ wherein each symbol is as defined in claim 1, and R^{a33} is hydroxyl group or C_{1-6} alkoxy.

15

25. The therapeutic agent of claim 1, wherein at least one group represented by group D is $-(CH_2)_t-O-(CH_2)_p-COR^{a21}$, wherein each symbol is as defined in claim 1, and R^{a21} is amino.

26. The therapeutic agent of claim 1, wherein at least one group represented by group D is $-(CH_2)_t-NR^{a29}CO-R^{a24}$ wherein each symbol is as defined in claim 1, and R^{a24} is amino or C_{1-6} alkylamino.

20


27. The therapeutic agent of claim 1, wherein at least one group represented by group D is $-(CH_2)_t-NR^{a22}R^{a23}$ wherein each symbol is as defined in claim 1, and at least one of R^{a22} and R^{a23} is heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the group B.

25

28. The therapeutic agent of claim 1, wherein at least one group represented by group D is heterocyclic group having 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom.

30

29. The therapeutic agent of claim 1, which comprises a fused ring compound of the following formula [I] or a pharmaceutically acceptable salt thereof as an active ingredient:



5 wherein

a broken line is a single bond or a double bond,

G^1 is $C(-R^1)$ or a nitrogen atom,

G^2 is $C(-R^2)$ or a nitrogen atom,

G^3 is $C(-R^3)$ or a nitrogen atom,

10 G^4 is $C(-R^4)$ or a nitrogen atom,

G^5 , G^6 , G^8 and G^9 are each independently a carbon atom or a nitrogen atom,

G^7 is $C(-R^7)$, an oxygen atom, a sulfur atom, or a nitrogen atom optionally substituted by R^8 ,

15 wherein R^1 , R^2 , R^3 and R^4 are each independently,

(1) hydrogen atom,

(2) C_{1-6} alkanoyl,

(3) carboxyl,

(4) cyano,

20 (5) nitro,

(6) C_{1-6} alkyl optionally substituted by 1 to 3

substituent(s) selected from the following group A,

group A; halogen atom, hydroxyl group, carboxyl, amino,

C_{1-6} alkoxy, C_{1-6} alkoxy carbonyl and C_{1-6}

25 alkylamino,

(7) $-COOR^{a1}$

wherein R^{a1} is optionally substituted C_{1-6} alkyl (as

defined above) or C_{6-14} aryl C_{1-6} alkyl optionally

substituted by 1 to 5 substituent(s) selected from the

30 following group B,

group B; halogen atom, cyano, nitro, C_{1-6} alkyl,

halogenated C_{1-6} alkyl, C_{1-6} alkanoyl,

$-(CH_2)_r-COOR^{b1}$, $-(CH_2)_r-CONR^{b1}R^{b2}$, $-(CH_2)_r-NR^{b1}R^{b2}$,
 $-(CH_2)_r-NR^{b1}-COR^{b2}$, $-(CH_2)_r-NHSO_2R^{b1}$, $-(CH_2)_r-OR^{b1}$,
 $-(CH_2)_r-SR^{b1}$, $-(CH_2)_r-SO_2R^{b1}$ and $-(CH_2)_r-SO_2NR^{b1}R^{b2}$
 wherein R^{b1} and R^{b2} are each independently
 hydrogen atom or C_{1-6} alkyl and r is 0 or an
 integer of 1 to 6,

(8) $-CONR^{a2}R^{a3}$

wherein R^{a2} and R^{a3} are each independently hydrogen atom,
 C_{1-6} alkoxy or optionally substituted C_{1-6} alkyl (as
 defined above),

(9) $-C(=NR^{a4})NH_2$

wherein R^{a4} is hydrogen atom or hydroxyl group,

(10) $-NHR^{a5}$

wherein R^{a5} is hydrogen atom, C_{1-6} alkanoyl or C_{1-6}
 alkylsulfonyl,

(11) $-OR^{a6}$

wherein R^{a6} is hydrogen atom or optionally substituted
 C_{1-6} alkyl (as defined above),

(12) $-SO_2R^{a7}$

wherein R^{a7} is hydroxyl group, amino, C_{1-6} alkyl or C_{1-6}
 alkylamino

or

(13) $-P(=O)(OR^{a31})_2$

wherein R^{a31} is hydrogen atom, optionally substituted C_{1-6}
 alkyl (as defined above) or C_{6-14} aryl C_{1-6} alkyl
 optionally substituted by 1 to 5 substituent(s)
 selected from the above group B, and


R^7 and R^8 are each hydrogen atom or optionally substituted
 C_{1-6} alkyl (as defined above),

30 ring Cy is

(1) C_{3-8} cycloalkyl optionally substituted by 1 to 5
 substituent(s) selected from the following group C,
 group C; hydroxyl group, halogen atom, C_{1-6} alkyl and
 C_{1-6} alkoxy,

(2) C_{3-8} cycloalkenyl optionally substituted by 1 to 5
 substituent(s) selected from the above group C, or

(3)



wherein u and v are each independently an integer of 1 to 3,

ring A is

- (1) C₆₋₁₄ aryl,
- (2) C₃₋₈ cycloalkyl,
- (3) C₃₋₈ cycloalkenyl or
- (4) heterocyclic group having 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom,

R⁵ and R⁶ are each independently

- (1) hydrogen atom,
- (2) halogen atom,
- (3) optionally substituted C₁₋₆ alkyl (as defined above) or
- (4) -OR^{a8}

wherein R^{a8} is hydrogen atom, C₁₋₆ alkyl or C₆₋₁₄ aryl C₁₋₆ alkyl, and

X is

- (1) hydrogen atom,
- (2) halogen atom,
- (3) cyano,
- (4) nitro,
- (5) amino, C₁₋₆ alkanoylamino,
- (6) C₁₋₆ alkylsulfonyl,
- (7) optionally substituted C₁₋₆ alkyl (as defined above),
- (8) C₂₋₆ alkenyl optionally substituted by 1 to 3 substituent(s) selected from the above group A,
- (9) -COOR^{a9}

wherein R^{a9} is hydrogen atom or C₁₋₆ alkyl,

- (10) -CONH-(CH₂)₁-R^{a10}


wherein R^{a10} is optionally substituted C₁₋₆ alkyl (as defined above), C₁₋₆ alkoxy carbonyl or C₁₋₆ alkanoylamino and l is 0 or an integer of 1 to 6,

(11) $-OR^{all}$

wherein R^{all} is hydrogen atom or optionally substituted C_{1-6} alkyl (as defined above)

or

(12)



wherein

ring B is

(1') C_{6-14} aryl,

(2') C_{3-8} cycloalkyl or

(3') heterocyclic group (as defined above),

each Z is independently

(1') a group selected from the following group D,

(2') C_{6-14} aryl optionally substituted by 1 to 5

substituent(s) selected from the following group D,

(3') C_{3-8} cycloalkyl optionally substituted by 1 to 5

substituent(s) selected from the following group D,

(4') C_{6-14} aryl C_{1-6} alkyl optionally substituted by 1 to 5 substituent(s) selected from the following group D or

(5') heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the following group D

wherein the heterocyclic group has 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom,

group D:

(a) hydrogen atom,

(b) halogen atom,

(c) cyano,

(d) nitro,

(e) optionally substituted C_{1-6} alkyl (as defined above),

(f) $-(CH_2)_t-COR^{a18}$,

(hereinafter each t means independently 0 or an integer of 1 to 6),

wherein R^{a18} is

(1") optionally substituted C₁₋₆ alkyl (as defined above),

(2") C₆₋₁₄ aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B or

(3") heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B

wherein the heterocyclic group has 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom,

(g) $-(CH_2)_t-COOR^{a19}$

wherein R^{a19} is hydrogen atom, optionally substituted C₁₋₆ alkyl (as defined above) or C₆₋₁₄ aryl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(h) $-(CH_2)_t-CONR^{a27}R^{a28}$

wherein R^{a27} and R^{a28} are each independently,

(1") hydrogen atom,

(2") optionally substituted C₁₋₆ alkyl (as defined above),

(3") C₆₋₁₄ aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(4") C₆₋₁₄ aryl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(5") heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(6") heterocycle C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

wherein the heterocycle C₁₋₆ alkyl is C₁₋₆ alkyl substituted by heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B, as defined above,

(7") C₃₋₈ cycloalkyl optionally substituted by 1

to 5 substituent(s) selected from the above group B, or

(8") C₃₋₈ cycloalkyl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(i) $-(CH_2)_t-C(=NR^{a33})NH_2$

wherein R^{a33} is hydrogen atom or C₁₋₆ alkyl,

(j) $-(CH_2)_t-OR^{a20}$

wherein R^{a20} is

(1") hydrogen atom,

(2") optionally substituted C₁₋₆ alkyl (as defined above),

(3") optionally substituted C₂₋₆ alkenyl (as defined above),

(4") C₂₋₆ alkynyl optionally substituted by 1 to 3 substituent(s) selected from the above group A,

(5") C₆₋₁₄ aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(6") C₆₋₁₄ aryl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(7") heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(8") heterocycle C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(9") C₃₋₈ cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B, or


(10") C₃₋₈ cycloalkyl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(k) $-(CH_2)_t-O-(CH_2)_p-COR^{a21}$

wherein R^{a21} is C₁₋₆ alkylamino or heterocyclic group optionally substituted by 1 to 5

substituent(s) selected from the above group B,

and p is 0 or an integer of 1 to 6,



wherein R^{a22} and R^{a23} are each independently


(1") hydrogen atom,

(2") optionally substituted C_{1-6} alkyl (as defined above),

(3") C_{6-14} aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,


(4") C_{6-14} aryl C_{1-6} alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B or

(5") heterocycle C_{1-6} alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,




wherein R^{a29} is hydrogen atom, C_{1-6} alkyl or C_{1-6} alkanoyl, R^{a24} is optionally substituted C_{1-6} alkyl (as defined above), C_{6-14} aryl optionally substituted by 1 to 5

substituent(s) selected from the above group B or heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,



wherein R^{a25} is hydrogen atom, optionally substituted C_{1-6} alkyl (as defined above),

C_{6-14} aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B or heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,



wherein R^{a25} is as defined above, and q is 0, 1 or 2,

and

(p) $-(CH_2)_t-SO_2-NHR^{a26}$

wherein R^{a26} is hydrogen atom, optionally substituted C_{1-6} alkyl (as defined above), C_{6-14} aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B or heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,

w is an integer of 1 to 3, and

Y is

(1') a single bond,

(2') C_{1-6} alkylene,

(3') C_{2-6} alkenylene,

(4') $-(CH_2)_m-O-(CH_2)_n-$,

(hereinafter m and n are each independently 0 or an integer of 1 to 6),

(5') $-CO-$,

(6') $-CO_2-(CH_2)_n-$,

(7') $-CONH-(CH_2)_n-NH-$,

(8') $-NHCO_2-$,

(9') $-NHCONH-$,

(10') $-O-(CH_2)_n-CO-$,

(11') $-O-(CH_2)_n-O-$,

(12') $-SO_2-$,

(13') $-(CH_2)_m-NR^{a12}-(CH_2)_n-$

wherein R^{a12} is

(1'') hydrogen atom,

(2'') optionally substituted C_{1-6} alkyl (as defined above),

(3'') C_{6-14} aryl C_{1-6} alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(4'') C_{6-14} aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(5'') $-COR^{b5}$

wherein R^{b5} is hydrogen atom, optionally substituted C_{1-6} alkyl (as defined above),

C₆₋₁₄ aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B or C₆₋₁₄ aryl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(6'') -COOR^{b5} (R^{b5} is as defined above) or

(7'') -SO₂R^{b5} (R^{b5} is as defined above),

(14') -NR^{a12}CO- (R^{a12} is as defined above),

(15') -CONR^{a13}-(CH₂)_n-

wherein R^{a13} is hydrogen atom, optionally substituted C₁₋₆ alkyl (as defined above) or C₆₋₁₄ aryl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(16') -CONH-CHR^{a14}-

wherein R^{a14} is C₆₋₁₄ aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(17') -O-(CH₂)_m-CR^{a15}R^{a16}-(CH₂)_n-

wherein R^{a15} and R^{a16} are each independently

(1'') hydrogen atom,

(2'') carboxyl,

(3'') C₁₋₆ alkyl,


(4'') -OR^{b6}

wherein R^{b6} is C₁₋₆ alkyl or C₆₋₁₄ aryl C₁₋₆ alkyl, or

(5'') -NHR^{b7}

wherein R^{b7} is hydrogen atom, C₁₋₆ alkyl, C₁₋₆ alkanoyl or C₆₋₁₄ aryl C₁₋₆ alkyloxycarbonyl, or R^{a15} is optionally

(6'')



wherein n', ring B', Z' and w' are the same as the above-mentioned n, ring B, Z and w, respectively, and may be the same as or different from the respective counterparts,

(18') $-(\text{CH}_2)_n-\text{NR}^{\text{a}12}-\text{CHR}^{\text{a}15}-$ ($\text{R}^{\text{a}12}$ and $\text{R}^{\text{a}15}$ are each as defined above),

(19') $-\text{NR}^{\text{a}17}\text{SO}_2-$

wherein $\text{R}^{\text{a}17}$ is hydrogen atom or C_{1-6} alkyl

or


(20') $-\text{S}(\text{O})_e-(\text{CH}_2)_m-\text{CR}^{\text{a}15}\text{R}^{\text{a}16}-(\text{CH}_2)_n-$ (e is 0, 1 or 2, $\text{R}^{\text{a}15}$ and $\text{R}^{\text{a}16}$ are each as defined above).

30. The therapeutic agent of claim 29, wherein 1 to 4 of the G^1 , G^2 , G^3 , G^4 , G^5 , G^6 , G^7 , G^8 and G^9 is(are) a nitrogen atom.


31. The therapeutic agent of claim 30, wherein G^2 is $\text{C}(-\text{R}^2)$ and G^6 is a carbon atom.

32. The therapeutic agent of claim 30, wherein G^5 is a nitrogen atom.


33. The therapeutic agent of claim 29, wherein, in formula [I], the moiety



is a fused ring selected from




34. The therapeutic agent of claim 33, wherein, in formula [I], the moiety




5

is a fused ring selected from




35. The therapeutic agent of claim 34, which comprises a fused ring compound of the following formula [I-1]



5


wherein each symbol is as defined in claim 29,
or a pharmaceutically acceptable salt thereof as an active
ingredient.

10 36. The therapeutic agent of claim 34, which comprises a fused ring compound of the following formula [I-2]



15 wherein each symbol is as defined in claim 29,
or a pharmaceutically acceptable salt thereof as an active
ingredient.


37. The therapeutic agent of claim 34, which comprises a fused ring compound of the following formula [I-3]



wherein each symbol is as defined in claim 29,
or a pharmaceutically acceptable salt thereof as an active
ingredient.

5

38. The therapeutic agent of claim 34, which comprises a fused
ring compound of the following formula [I-4]




wherein each symbol is as defined in claim 29,
10 or a pharmaceutically acceptable salt thereof as an active
ingredient.

39. The therapeutic agent of claim 29, wherein at least one of R¹,
R², R³ and R⁴ is carboxyl, -COOR^{a1}, -CONR^{a2}R^{a3} or -SO₂R^{a7} wherein R^{a1},
15 R^{a2}, R^{a3} and R^{a7} are as defined in claim 29.


40. The therapeutic agent of claim 29, wherein the ring Cy is
cyclopentyl, cyclohexyl, cycloheptyl or tetrahydrothiopyranyl.

20 41. The therapeutic agent of claim 29, wherein the ring A is C₆₋₁₄
aryl.


42. A fused ring compound of the following formula [II]



wherein
the moiety



5 is a fused ring selected from



wherein R^1 , R^2 , R^3 and R^4 are each independently,

- (1) hydrogen atom,
- (2) C_{1-6} alkanoyl,
- (3) carboxyl,
- (4) cyano,
- (5) nitro,

- (6) C_{1-6} alkyl optionally substituted by 1 to 3

substituent(s) selected from the following group A,

group A; halogen atom, hydroxyl group, carboxyl, amino,
 C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkoxy, C_{1-6}
alkoxycarbonyl and C_{1-6} alkylamino,

- (7) $-COOR^{a1}$

wherein R^{a1} is optionally substituted C_{1-6} alkyl (as
defined above), C_{6-14} aryl C_{1-6} alkyl optionally
substituted by 1 to 5 substituent(s) selected from the
following group B or glucuronic acid residue,
group B; halogen atom, cyano, nitro, C_{1-6} alkyl,

halogenated C_{1-6} alkyl, C_{1-6} alkanoyl,
 $-(CH_2)_r-COOR^{b1}$, $-(CH_2)_r-CONR^{b1}R^{b2}$, $-(CH_2)_r-NR^{b1}R^{b2}$,

$-(CH_2)_r-NR^{b1}-COR^{b2}$, $-(CH_2)_r-NHSO_2R^{b1}$, $-(CH_2)_r-OR^{b1}$,
 $-(CH_2)_r-SR^{b1}$, $-(CH_2)_r-SO_2R^{b1}$ and $-(CH_2)_r-SO_2NR^{b1}R^{b2}$
 wherein R^{b1} and R^{b2} are each independently
 hydrogen atom or C_{1-6} alkyl and r is 0 or an
 integer of 1 to 6,

(8) $-CONR^{a2}R^{a3}$

wherein R^{a2} and R^{a3} are each independently hydrogen atom,
 C_{1-6} alkoxy or optionally substituted C_{1-6} alkyl (as
 defined above),

(9) $-C(=NR^{a4})NH_2$

wherein R^{a4} is hydrogen atom or hydroxyl group,

(10) $-NHR^{a5}$

wherein R^{a5} is hydrogen atom, C_{1-6} alkanoyl or C_{1-6}
 alkylsulfonyl,

(11) $-OR^{a6}$

wherein R^{a6} is hydrogen atom or optionally substituted
 C_{1-6} alkyl (as defined above),

(12) $-SO_2R^{a7}$

wherein R^{a7} is hydroxyl group, amino, C_{1-6} alkyl or C_{1-6}
 alkylamino,

(13) $-P(=O)(OR^{a31})_2$

wherein R^{a31} is hydrogen atom, optionally substituted C_{1-6}
 alkyl (as defined above) or C_{6-14} aryl C_{1-6} alkyl
 optionally substituted by 1 to 5 substituent(s)
 selected from the above group B,

or

(14) heterocyclic group having 1 to 4 heteroatom(s)

selected from an oxygen atom, a nitrogen atom and a
 sulfur atom, and

R^7 is hydrogen atom or optionally substitute C_{1-6} alkyl (as
 defined above),


ring Cy' is

(1) C_{3-8} cycloalkyl optionally substituted by 1 to 5

substituent(s) selected from the following group C,

group C; hydroxyl group, halogen atom, C_{1-6} alkyl and
 C_{1-6} alkoxy, or

(2)



wherein u and v are each independently an integer of 1 to 3,

ring A' is a group selected from a group consisting of phenyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, cyclohexyl, cyclohexenyl, furyl and thienyl,

R^{5'} and R^{6'} are each independently

- (1) hydrogen atom,
- (2) halogen atom,
- (3) optionally substituted C₁₋₆ alkyl (as defined above) or
- (4) hydroxyl group

ring B is

- (1) C₆₋₁₄ aryl,
- (2) C₃₋₈ cycloalkyl or
- (3) heterocyclic group having 1 to 4 heteroatom(s)

selected

from an oxygen atom, a nitrogen atom and a sulfur atom,

each Z is independently

- (1) a group selected from the following group D,
- (2) C₆₋₁₄ aryl optionally substituted by 1 to 5 substituent(s) selected from the following group D,
- (3) C₃₋₈ cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from the following group D,
- (4) C₆₋₁₄ aryl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the following group D,
- (5) heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the following group D wherein the heterocyclic group has 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom, or
- (6) heterocycle C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the following group D wherein the heterocycle C₁₋₆ alkyl is C₁₋₆ alkyl substituted by heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the

group D, as defined above,

group D:

- (a) hydrogen atom,
- (b) halogen atom,
- (c) cyano,
- (d) nitro,
- (e) optionally substituted C_{1-6} alkyl (as defined above),
- (f) $-(CH_2)_t-COR^{a18}$,

(hereinafter each t means independently 0 or an integer of 1 to 6),

wherein R^{a18} is

- (1') optionally substituted C_{1-6} alkyl (as defined above),
 - (2') C_{6-14} aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B or
 - (3') heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B
- wherein the heterocyclic group has 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom,

- (g) $-(CH_2)_t-COOR^{a19}$

wherein R^{a19} is hydrogen atom, optionally substituted C_{1-6} alkyl (as defined above) or C_{6-14} aryl C_{1-6} alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

- (h) $-(CH_2)_t-CONR^{a27}R^{a28}$

wherein R^{a27} and R^{a28} are each independently,

- (1'') hydrogen atom,
- (2'') optionally substituted C_{1-6} alkyl (as defined above),
- (3'') C_{6-14} aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (4'') C_{6-14} aryl C_{1-6} alkyl optionally substituted

by 1 to 5 substituent(s) selected from the
above group B,

(5'') heterocyclic group optionally substituted by
1 to 5 substituent(s) selected from the above
group B,

(6'') heterocycle C₁₋₆ alkyl optionally
substituted by 1 to 5 substituent(s) selected
from the above group B,

wherein the heterocycle C₁₋₆ alkyl is C₁₋₆ alkyl
substituted by heterocyclic group optionally
substituted by 1 to 5 substituent(s) selected
from the above group B, as defined above,

(7'') C₃₋₈ cycloalkyl optionally substituted by 1
to 5 substituent(s) selected from the above
group B,

(8'') C₃₋₈ cycloalkyl C₁₋₆ alkyl optionally
substituted by 1 to 5 substituent(s) selected
from the above group B,

(9'') hydroxyl group or

(10'') C₁₋₆ alkoxy,

(i) $-(CH_2)_t-C(=NR^{a33})NH_2$

wherein R^{a33} is hydrogen atom, C₁₋₆ alkyl,
hydroxyl group or C₁₋₆ alkoxy,

(j) $-(CH_2)_t-OR^{a20}$

wherein R^{a20} is

(1') hydrogen atom,

(2') optionally substituted C₁₋₆ alkyl (as
defined above),

(3') optionally substituted C₂₋₆ alkenyl (as
defined above),

(4') C₂₋₆ alkynyl optionally substituted by 1
to 3 substituent(s) selected from the
above group A,

(5') C₆₋₁₄ aryl optionally substituted by 1 to
5 substituent(s) selected from the above
group B,

(6') C₆₋₁₄ aryl C₁₋₆ alkyl optionally
substituted by 1 to 5 substituent(s)

- selected from the above group B,
- (7') heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (8') heterocycle C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (9') C₃₋₈ cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B, or
- (10') C₃₋₈ cycloalkyl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (k) $-(CH_2)_t-O-(CH_2)_p-COR^{a21}$
 wherein R^{a21} is amino, C₁₋₆ alkylamino or heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,
 and p is 0 or an integer of 1 to 6,
- (l) $-(CH_2)_t-NR^{a22}R^{a23}$
 wherein R^{a22} and R^{a23} are each independently
- (1') hydrogen atom,
- (2') optionally substituted C₁₋₆ alkyl (as defined above),
- (3') C₆₋₁₄ aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (4') C₆₋₁₄ aryl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (5') heterocycle C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B or
- (6') heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (m) $-(CH_2)_t-NR^{a29}CO-R^{a24}$
 wherein R^{a29} is hydrogen atom, C₁₋₆ alkyl or C₁₋₆

alkanoyl, and

R^{a24} is

(1') amino,

(2') C_{1-6} alkylamino,

(3') optionally substituted C_{1-6}
alkyl (as defined above),

(4') C_{6-14} aryl optionally substituted by 1 to
5 substituent(s) selected from the above
group B,

(5') heterocyclic group optionally
substituted by 1 to 5 substituent(s)
selected from the above group B, or

(6') heterocycle C_{1-6} alkyl optionally
substituted by 1 to 5 substituent(s)
selected from the above group B,

(n) $-(CH_2)_t-NR^{a29}SO_2-R^{a25}$

wherein R^{a29} is as defined above, and

R^{a25} is hydrogen atom, optionally
substituted C_{1-6} alkyl (as defined above),

C_{6-14} aryl optionally substituted by 1 to 5
substituent(s) selected from the above group
B

or heterocyclic group optionally substituted
by 1 to 5 substituent(s) selected from the
above group B,

(o) $-(CH_2)_t-S(O)_q-R^{a25}$

wherein R^{a25} is as defined above, and q is 0, 1
or 2,

(p) $-(CH_2)_t-SO_2-NHR^{a26}$

wherein R^{a26} is hydrogen atom, optionally
substituted C_{1-6} alkyl (as defined above),

C_{6-14} aryl optionally substituted by 1 to 5
substituent(s) selected from the above group
B

or heterocyclic group optionally substituted
by 1 to 5 substituent(s) selected from the
above group B,

and

(q) heterocyclic group having 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom,

W is an integer of 1 to 3, and

5 Y is

- (1) a single bond,
- (2) C₁₋₆ alkylene,
- (3) C₂₋₆ alkenylene,
- (4) -(CH₂)_m-O-(CH₂)_n-,

10 (hereinafter m and n are each independently 0 or an integer of 1 to 6),

- (5) -CO-,
- (6) -CO₂-(CH₂)_n-,
- (7) -CONH-(CH₂)_n-NH-,
- 15 (8) -NHCO₂-,
- (9) -NHCONH-,
- (10) -O-(CH₂)_n-CO-,
- (11) -O-(CH₂)_n-O-,
- (12) -SO₂-,
- 20 (13) -(CH₂)_m-NR^{al2}-(CH₂)_n-

wherein R^{al2} is

- (1') hydrogen atom,
- (2') optionally substituted C₁₋₆ alkyl (as defined above),
- 25 (3') C₆₋₁₄ aryl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (4') C₆₋₁₄ aryl optionally substituted by 1 to 5 substituent(s) selected from the above
- 30 group B,
- (5') -COR^{b5}

wherein R^{b5} is hydrogen atom, optionally substituted C₁₋₆ alkyl (as defined above), C₆₋₁₄ aryl optionally substituted by 1 to 5 substituent(s) selected from the above

35 group B or C₆₋₁₄ aryl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above

group B,

(6') $-\text{COOR}^{b5}$ (R^{b5} is as defined above) or

(7') $-\text{SO}_2\text{R}^{b5}$ (R^{b5} is as defined above),

(14) $-\text{NR}^{a12}\text{CO}-$ (R^{a12} is as defined above),

(15) $-\text{CONR}^{a13}-(\text{CH}_2)_n-$

wherein R^{a13} is hydrogen atom, optionally substituted C_{1-6} alkyl (as defined above) or C_{6-14} aryl C_{1-6} alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(16) $-\text{CONH}-\text{CHR}^{a14}-$

wherein R^{a14} is C_{6-14} aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(17) $-\text{O}-(\text{CH}_2)_m-\text{CR}^{a15}\text{R}^{a16}-(\text{CH}_2)_n-$

wherein R^{a15} and R^{a16} are each independently

(1') hydrogen atom,

(2') carboxyl,

(3') C_{1-6} alkyl,


(4') $-\text{OR}^{b6}$

wherein R^{b6} is C_{1-6} alkyl or C_{6-14} aryl C_{1-6} alkyl, or

(5') $-\text{NHR}^{b7}$

wherein R^{b7} is hydrogen atom, C_{1-6} alkyl, C_{1-6} alkanoyl or C_{6-14} aryl C_{1-6} alkyloxycarbonyl, or R^{a15} is optionally

(6')



wherein n' , ring B' , Z' and w' are the same as the above-mentioned n , ring B , Z and w , respectively, and may be the same as or different from the respective counterparts,

(18) $-(\text{CH}_2)_n-\text{NR}^{a12}-\text{CHR}^{a15}-$ (R^{a12} and R^{a15} are each as defined above),

(19) $-\text{NR}^{a17}\text{SO}_2-$

wherein R^{a17} is hydrogen atom or C_{1-6} alkyl,

(20) $-\text{S}(\text{O})_e-(\text{CH}_2)_m-\text{CR}^{a15}\text{R}^{a16}-(\text{CH}_2)_n-$ (e is 0, 1 or 2,


R^{a15} and R^{a16} are each as defined above),

or

(21) $-(CH_2)_m-CR^{a15}R^{a16}-(CH_2)_n-$ (R^{a15} and R^{a16} are each as defined above),


5 or a pharmaceutically acceptable salt thereof.

43. The fused ring compound of claim 42, which is represented by the following formula [II-1]




10 wherein each symbol is as defined in claim 42,
or a pharmaceutically acceptable salt thereof.

44. The fused ring compound of claim 42, which is represented by the following formula [II-2]




15 wherein each symbol is as defined in claim 42,
or a pharmaceutically acceptable salt thereof.

45. The fused ring compound of claim 42, which is represented by
20 the following formula [II-3]



wherein each symbol is as defined in claim 42,
or a pharmaceutically acceptable salt thereof.


- 5 46. The fused ring compound of claim 42, which is represented by
the following formula [II-4]



wherein each symbol is as defined in claim 42,
or a pharmaceutically acceptable salt thereof.

10

47. The fused ring compound of claim 42, wherein at least one of
 R^1 , R^2 , R^3 and R^4 is carboxyl, $-\text{COOR}^{a1}$, $-\text{CONR}^{a2}\text{R}^{a3}$,
 $-\text{SO}_2\text{R}^{a7}$ (wherein R^{a1} , R^{a2} , R^{a3} and R^{a7} are as defined in claim 42),



- 15 or a pharmaceutically acceptable salt thereof.

48. The fused ring compound of claim 47, wherein at least one of
 R^1 , R^2 , R^3 and R^4 is carboxyl, $-\text{COOR}^{a1}$ or $-\text{SO}_2\text{R}^{a7}$ wherein R^{a1} and R^{a7}
20 thereof.

49. The fused ring compound of claim 48, wherein at least one of R^1 , R^2 , R^3 and R^4 is carboxyl or $-COOR^{a1}$ wherein R^{a1} is as defined in claim 42, or a pharmaceutically acceptable salt thereof.

50. The fused ring compound of claim 49, wherein R^2 is carboxyl and R^1 , R^3 and R^4 are hydrogen atoms, or a pharmaceutically acceptable salt thereof.


51. The fused ring compound of claim 42, wherein at least one of R^1 , R^2 , R^3 and R^4 is carboxyl or $-COOR^{a1}$ wherein R^{a1} is glucuronic acid residue, or a pharmaceutically acceptable salt thereof.

52. The fused ring compound of claim 42, wherein at least one of R^1 , R^2 , R^3 and R^4 is heterocyclic group having 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom, or a pharmaceutically acceptable salt thereof.

53. The fused ring compound of claim 42, wherein the ring Cy' is cyclopentyl, cyclohexyl, cycloheptyl or tetrahydrothiopyranyl, or a pharmaceutically acceptable salt thereof.

54. The fused ring compound of claim 42, wherein the ring Cy' is cyclopentyl, cyclohexyl or cycloheptyl, or a pharmaceutically acceptable salt thereof.

55. The fused ring compound of claim 42, wherein the ring Cy' is



wherein each symbol is as defined in claim 42, or a pharmaceutically acceptable salt thereof.

56. The fused ring compound of claim 42, wherein the ring A' is phenyl, pyridyl, pyrazinyl, pyrimidinyl or pyridazinyl, or a pharmaceutically acceptable salt thereof.

57. The fused ring compound of claim 56, wherein the ring A' is phenyl or pyridyl, or a pharmaceutically acceptable salt thereof.

58. The fused ring compound of claim 57, wherein the ring A' is phenyl, or a pharmaceutically acceptable salt thereof.

59. The fused ring compound of claim 42, wherein at least one substituent optionally substituted by group A is a substituent substituted by C₁₋₆ alkoxy C₁₋₆ alkoxy, or a pharmaceutically acceptable salt thereof.

60. The fused ring compound of claim 42, wherein the Y is $-(CH_2)_m-O-(CH_2)_n-$, $-NHCO_2-$, $-CONH-CHR^{a14}-$, $-(CH_2)_m-NR^{a12}-(CH_2)_n-$, $-CONR^{a13}-(CH_2)_n-$, $-O-(CH_2)_m-CR^{a15}R^{a16}-(CH_2)_n-$ or $-(CH_2)_n-NR^{a12}-CHR^{a15}-$ (wherein each symbol is as defined in claim 42), or a pharmaceutically acceptable salt thereof.

61. The fused ring compound of claim 42, wherein the Y is $-(CH_2)_m-O-(CH_2)_n-$ or $-O-(CH_2)_m-CR^{a15}R^{a16}-(CH_2)_n-$ (wherein each symbol is as defined in claim 42), or a pharmaceutically acceptable salt thereof.

62. The fused ring compound of claim 61, wherein the Y is $-(CH_2)_m-O-(CH_2)_n-$ wherein each symbol is as defined in claim 42, or a pharmaceutically acceptable salt thereof.


63. The fused ring compound of claim 42, wherein the Y is $-(CH_2)_m-CR^{a15}R^{a16}-(CH_2)_n-$ (wherein each symbol is as defined in claim 42), or a pharmaceutically acceptable salt thereof.

64. The fused ring compound of claim 42, wherein the R² is carboxyl, R¹, R³ and R⁴ are hydrogen atoms, the ring Cy' is cyclopentyl, cyclohexyl or cycloheptyl, and the ring A' is phenyl, or a pharmaceutically acceptable salt thereof.

65. The fused ring compound of claim 42, wherein at least one group represented by Z is heterocycle C₁₋₆ alkyl optionally


substituted by 1 to 5 substituent(s) selected from the group D,
or a pharmaceutically acceptable salt thereof.

66. The fused ring compound of claim 42, wherein at least one
5 group represented by Z is heterocyclic group optionally
substituted by 1 to 5 substituent(s) selected from the group D,
wherein said heterocyclic group is selected from the following
groups:



wherein E^1 is an oxygen atom, a sulfur atom or $N(-R^{a35})$, E^2 is an oxygen atom, CH_2 or $N(-R^{a35})$, E^3 is an oxygen atom or a sulfur atom, wherein each R^{a35} is independently hydrogen atom or C_{1-6} alkyl, f is an integer of 1 to 3, and h and h' are the same or different
 5 and each is an integer of 1 to 3, or a pharmaceutically acceptable salt thereof.

67. The fused ring compound of claim 66, wherein at least one group represented by Z is heterocyclic group optionally
 10 substituted by 1 to 5 substituent(s) selected from the group D, wherein said heterocyclic group is selected from the following groups:



wherein each symbol is as defined in claim 66, or a
 15 pharmaceutically acceptable salt thereof.

68. The fused ring compound of claim 42, wherein at least one group represented by group D is $-(CH_2)_t-CONR^{a27}R^{a28}$ wherein each symbol is as defined in claim 42, and at least one of R^{a27} and R^{a28}
 20 is C_{1-6} alkoxy, or a pharmaceutically acceptable salt thereof.

69. The fused ring compound of claim 42, wherein at least one group represented by group D is $-(CH_2)_t-C(=NR^{a33})NH_2$ wherein each symbol is as defined in claim 42, and R^{a33} is hydroxyl group or
 25 C_{1-6} alkoxy, or a pharmaceutically acceptable salt thereof.

70. The fused ring compound of claim 42, wherein at least one group represented by group D is $-(CH_2)_t-O-(CH_2)_p-COR^{a21}$ wherein each symbol is as defined in claim 42, and R^{a21} is amino, or a
 30 pharmaceutically acceptable salt thereof.

71. The fused ring compound of claim 42, wherein at least one group represented by group D is $-(CH_2)_t-NR^{a29}CO-R^{a24}$ wherein each

symbol is as defined in claim 42, and R^{a24} is amino or C_{1-6} alkylamino, or a pharmaceutically acceptable salt thereof.


72. The fused ring compound of claim 42, wherein at least one group represented by group D is $-(CH_2)_t-NR^{a22}R^{a23}$ wherein each symbol is as defined in claim 42, and at least one of R^{a22} and R^{a23} is heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the group B, or a pharmaceutically acceptable salt thereof.

10

73. The fused ring compound of claim 42, wherein at least one group represented by group D is heterocyclic group having 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom, or a pharmaceutically acceptable salt thereof.


15

74. The fused ring compound of claim 42, which is represented by the following formula [II]




wherein

20 the moiety



is a fused ring selected from



wherein R^1 , R^2 , R^3 and R^4 are each independently,
(1) hydrogen atom,

25

- (2) C₁₋₆ alkanoyl,
- (3) carboxyl,
- (4) cyano,
- (5) nitro,
- 5 (6) C₁₋₆ alkyl optionally substituted by 1 to 3
substituent(s) selected from the following group A,
group A; halogen atom, hydroxyl group, carboxyl, amino,
C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl and C₁₋₆
alkylamino,
- 10 (7) -COOR^{a1}
wherein R^{a1} is optionally substituted C₁₋₆ alkyl (as
defined above) or C₆₋₁₄ aryl C₁₋₆ alkyl optionally
substituted by 1 to 5 substituent(s) selected from the
following group B,
- 15 group B; halogen atom, cyano, nitro, C₁₋₆ alkyl,
halogenated C₁₋₆ alkyl, C₁₋₆ alkanoyl,
-(CH₂)_r-COOR^{b1}, -(CH₂)_r-CONR^{b1}R^{b2}, -(CH₂)_r-NR^{b1}R^{b2},
-(CH₂)_r-NR^{b1}-COR^{b2}, -(CH₂)_r-NHSO₂R^{b1}, -(CH₂)_r-OR^{b1},
-(CH₂)_r-SR^{b1}, -(CH₂)_r-SO₂R^{b1} and -(CH₂)_r-SO₂NR^{b1}R^{b2}
20 wherein R^{b1} and R^{b2} are each independently
hydrogen atom or C₁₋₆ alkyl and r is 0 or an
integer of 1 to 6,
- (8) -CONR^{a2}R^{a3}
wherein R^{a2} and R^{a3} are each independently hydrogen atom,
25 C₁₋₆ alkoxy or optionally substituted C₁₋₆ alkyl (as
defined above),
- (9) -C(=NR^{a4})NH₂
wherein R^{a4} is hydrogen atom or hydroxyl group,
- (10) -NHR^{a5}
30 wherein R^{a5} is hydrogen atom, C₁₋₆ alkanoyl or C₁₋₆
alkylsulfonyl,
- (11) -OR^{a6}
wherein R^{a6} is hydrogen atom or optionally substituted
C₁₋₆ alkyl (as defined above),
- 35 (12) -SO₂R^{a7}
wherein R^{a7} is hydroxyl group, amino, C₁₋₆ alkyl or C₁₋₆
alkylamino

or

(13) $-P(=O)(OR^{a31})_2$

wherein R^{a31} is hydrogen atom, optionally substituted C_{1-6} alkyl (as defined above) or C_{6-14} aryl C_{1-6} alkyl optionally substituted by 1 to 5 substituent(s)


5 selected from the above group B, and

R^7 is hydrogen atom or optionally substituted C_{1-6} alkyl (as defined above),

ring Cy' is

10 (1) C_{3-8} cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from the following group C, group C; hydroxyl group, halogen atom, C_{1-6} alkyl and C_{1-6} alkoxy, or

(2)



15 wherein u and v are each independently an integer of 1 to 3,

ring A' is a group selected from a group consisting of phenyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, cyclohexyl, cyclohexenyl, furyl and thienyl,

20 $R^{5'}$ and $R^{6'}$ are each independently

(1) hydrogen atom,

(2) halogen atom,

(3) optionally substituted C_{1-6} alkyl (as defined above) or

(4) hydroxyl group

25 ring B is

(1) C_{6-14} aryl,

(2) C_{3-8} cycloalkyl or

(3) heterocyclic group having 1 to 4 heteroatom(s)

selected from an oxygen atom, a nitrogen atom and a sulfur atom,

30 each Z is independently

(1) a group selected from the following group D,

(2) C_{6-14} aryl optionally substituted by 1 to 5 substituent(s) selected from the following group D,

35 (3) C_{3-8} cycloalkyl optionally substituted by 1 to 5

substituent(s) selected from the following group D,

(4) C₆₋₁₄ aryl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the following group D or

(5) heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the following group D wherein the heterocyclic group has 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom,

group D:

(a) hydrogen atom,

(b) halogen atom,

(c) cyano,

(d) nitro,

(e) optionally substituted C₁₋₆ alkyl (as defined above),

(f) $-(CH_2)_t-COR^{a18}$,

(hereinafter each t means independently 0 or an integer of 1 to 6),

wherein R^{a18} is

(1') optionally substituted C₁₋₆ alkyl (as defined above),

(2') C₆₋₁₄ aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B or

(3') heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B

wherein the heterocyclic group has 1 to 4 heteroatom(s) selected from an oxygen atom, a nitrogen atom and a sulfur atom,

(g) $-(CH_2)_t-COOR^{a19}$

wherein R^{a19} is hydrogen atom, optionally substituted C₁₋₆ alkyl (as defined above) or C₆₋₁₄ aryl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(h) $-(CH_2)_t-CONR^{a27}R^{a28}$

wherein R^{a27} and R^{a28} are each independently,

- (1'') hydrogen atom,
- (2'') optionally substituted C₁₋₆ alkyl (as defined above),
- (3'') C₆₋₁₄ aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (4'') C₆₋₁₄ aryl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (5'') heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (6'') heterocycle C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- wherein the heterocycle C₁₋₆ alkyl is C₁₋₆ alkyl substituted by heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B, as defined above,
- (7'') C₃₋₈ cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B, or
- (8'') C₃₋₈ cycloalkyl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (i) $-(CH_2)_t-C(=NR^{a33})NH_2$
wherein R^{a33} is hydrogen atom or C₁₋₆ alkyl,
- (j) $-(CH_2)_t-OR^{a20}$
wherein R^{a20} is
- (1') hydrogen atom,
- (2') optionally substituted C₁₋₆ alkyl (as defined above),
- (3') optionally substituted C₂₋₆ alkenyl (as defined above),
- (4') C₂₋₆ alkynyl optionally substituted by 1 to 3 substituent(s) selected from the above group A,
- (5') C₆₋₁₄ aryl optionally substituted by 1 to

- 5 substituent(s) selected from the above group B,
- (6') C₆₋₁₄ aryl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (7') heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (8') heterocycle C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (9') C₃₋₈ cycloalkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B, or
- (10') C₃₋₈ cycloalkyl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (k) $-(CH_2)_t-O-(CH_2)_p-COR^{a21}$
 wherein R^{a21} is C₁₋₆ alkylamino or heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,
 and p is 0 or an integer of 1 to 6,
- (l) $-(CH_2)_t-NR^{a22}R^{a23}$
 wherein R^{a22} and R^{a23} are each independently
- (1') hydrogen atom,
- (2') optionally substituted C₁₋₆ alkyl (as defined above),
- (3') C₆₋₁₄ aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (4') C₆₋₁₄ aryl C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B or
- (5') heterocycle C₁₋₆ alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
- (m) $-(CH_2)_t-NR^{a29}CO-R^{a24}$

wherein R^{a29} is hydrogen atom, C_{1-6} alkyl or C_{1-6} alkanoyl, R^{a24} is optionally substituted C_{1-6} alkyl (as defined above), C_{6-14} aryl optionally

substituted by 1 to 5 substituent(s) selected from the above group B or heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(n) $-(CH_2)_t-NHSO_2-R^{a25}$

wherein R^{a25} is hydrogen atom, optionally substituted C_{1-6} alkyl (as defined above), C_{6-14} aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B

or heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(o) $-(CH_2)_t-S(O)_q-R^{a25}$

wherein R^{a25} is as defined above, and q is 0, 1 or 2,

and

(p) $-(CH_2)_t-SO_2-NHR^{a26}$

wherein R^{a26} is hydrogen atom, optionally substituted C_{1-6} alkyl (as defined above), C_{6-14} aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B

or heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above group B,

is an integer of 1 to 3, and

is

(1) a single bond,

(2) C_{1-6} alkylene,

(3) C_{2-6} alkenylene,

(4) $-(CH_2)_m-O-(CH_2)_n-$,

(hereinafter m and n are each independently 0

or an integer of 1 to 6),

- (5) $-\text{CO}-$,
(6) $-\text{CO}_2-(\text{CH}_2)_n-$,
(7) $-\text{CONH}-(\text{CH}_2)_n-\text{NH}-$,
(8) $-\text{NHCO}_2-$,
(9) $-\text{NHCONH}-$,
(10) $-\text{O}-(\text{CH}_2)_n-\text{CO}-$,
(11) $-\text{O}-(\text{CH}_2)_n-\text{O}-$,
(12) $-\text{SO}_2-$,
(13) $-(\text{CH}_2)_m-\text{NR}^{\text{a}12}-(\text{CH}_2)_n-$

wherein $\text{R}^{\text{a}12}$ is

- (1') hydrogen atom,
(2') optionally substituted C_{1-6} alkyl (as defined above),
(3') C_{6-14} aryl C_{1-6} alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
(4') C_{6-14} aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,
(5') $-\text{COR}^{\text{b}5}$

wherein $\text{R}^{\text{b}5}$ is hydrogen atom, optionally substituted C_{1-6} alkyl (as defined above), C_{6-14} aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B or C_{6-14} aryl C_{1-6} alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

- (6') $-\text{COOR}^{\text{b}5}$ ($\text{R}^{\text{b}5}$ is as defined above) or
(7') $-\text{SO}_2\text{R}^{\text{b}5}$ ($\text{R}^{\text{b}5}$ is as defined above),
(14) $-\text{NR}^{\text{a}12}\text{CO}-$ ($\text{R}^{\text{a}12}$ is as defined above),
(15) $-\text{CONR}^{\text{a}13}-(\text{CH}_2)_n-$

wherein $\text{R}^{\text{a}13}$ is hydrogen atom, optionally substituted C_{1-6} alkyl (as defined above) or C_{6-14} aryl C_{1-6} alkyl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(16) $-\text{CONH}-\text{CHR}^{\text{a14}}-$

wherein R^{a14} is C_{6-14} aryl optionally substituted by 1 to 5 substituent(s) selected from the above group B,

(17) $-\text{O}-(\text{CH}_2)_m-\text{CR}^{\text{a15}}\text{R}^{\text{a16}}-(\text{CH}_2)_n-$

wherein R^{a15} and R^{a16} are each independently

(1') hydrogen atom,

(2') carboxyl,

(3') C_{1-6} alkyl,


(4') $-\text{OR}^{\text{b6}}$

wherein R^{b6} is C_{1-6} alkyl or C_{6-14} aryl C_{1-6} alkyl, or

(5') $-\text{NHR}^{\text{b7}}$

wherein R^{b7} is hydrogen atom, C_{1-6} alkyl, C_{1-6} alkanoyl or C_{6-14} aryl C_{1-6} alkyloxycarbonyl, or R^{a15} is optionally

(6')



wherein n' , ring B' , Z' and w' are the same as the above-mentioned n , ring B , Z and w , respectively, and may be the same as or different from the respective counterparts,

(18) $-(\text{CH}_2)_n-\text{NR}^{\text{a12}}-\text{CHR}^{\text{a15}}-$ (R^{a12} and R^{a15} are each as defined above),

(19) $-\text{NR}^{\text{a17}}\text{SO}_2-$


wherein R^{a17} is hydrogen atom or C_{1-6} alkyl

or

(20) $-\text{S}(\text{O})_e-(\text{CH}_2)_m-\text{CR}^{\text{a15}}\text{R}^{\text{a16}}-(\text{CH}_2)_n-$ (e is 0, 1 or 2, R^{a15} and R^{a16} are each as defined above),


or a pharmaceutically acceptable salt thereof.

75. The fused ring compound of claim 74, which is represented by the following formula [II-1]



wherein each symbol is as defined in claim 74,
or a pharmaceutically acceptable salt thereof.


- 5 76. The fused ring compound of claim 74, which is represented by
the following formula [II-2]



wherein each symbol is as defined in claim 74,
or a pharmaceutically acceptable salt thereof.


10

77. The fused ring compound of claim 74, which is represented by
the following formula [II-3]



- wherein each symbol is as defined in claim 74,
15 or a pharmaceutically acceptable salt thereof.

78. The fused ring compound of claim 74, which is represented by
the following formula [II-4]



wherein each symbol is as defined in claim 74,
or a pharmaceutically acceptable salt thereof.

79. The fused ring compound of claim 74, wherein at least one of R^1 , R^2 , R^3 and R^4 is carboxyl, $-\text{COOR}^{a1}$ or $-\text{SO}_2\text{R}^{a7}$ wherein R^{a1} and R^{a7} are as defined in claim 74, or a pharmaceutically acceptable salt thereof.

80. The fused ring compound of claim 79, wherein at least one of R^1 , R^2 , R^3 and R^4 is carboxyl or $-\text{COOR}^{a1}$ wherein R^{a1} is as defined in claim 74, or a pharmaceutically acceptable salt thereof.

81. The fused ring compound of claim 80, wherein R^2 is carboxyl and R^1 , R^3 and R^4 are hydrogen atoms, or a pharmaceutically acceptable salt thereof.

82. The fused ring compound of claim 74, wherein the ring Cy' is cyclopentyl, cyclohexyl, cycloheptyl or tetrahydrothiopyranyl, or a pharmaceutically acceptable salt thereof.

83. The fused ring compound of claim 82, wherein the ring Cy' is cyclopentyl, cyclohexyl or cycloheptyl, or a pharmaceutically acceptable salt thereof.

84. The fused ring compound of claim 74, wherein the ring A' is phenyl, pyridyl, pyrazinyl, pyrimidinyl or pyridazinyl, or a pharmaceutically acceptable salt thereof.

85. The fused ring compound of claim 74, wherein the ring A' is phenyl or pyridyl, or a pharmaceutically acceptable salt thereof.

86. The fused ring compound of claim 85, wherein the ring A' is phenyl, or a pharmaceutically acceptable salt thereof.
87. The fused ring compound of claim 74, wherein the Y is
 5 $-(CH_2)_m-O-(CH_2)_n-$, $-NHCO_2-$, $-CONH-CHR^{a14}-$, $-(CH_2)_m-NR^{a12}-(CH_2)_n-$,
 $-CONR^{a13}-(CH_2)_n-$, $-O-(CH_2)_m-CR^{a15}R^{a16}-(CH_2)_n-$ or $-(CH_2)_n-NR^{a12}-CHR^{a15}-$
 (wherein each symbol is as defined in claim 74), or a pharmaceutically acceptable salt thereof.
- 10 88. The fused ring compound of claim 87, wherein the Y is
 $-(CH_2)_m-O-(CH_2)_n-$ or $-O-(CH_2)_m-CR^{a15}R^{a16}-(CH_2)_n-$ (wherein each symbol is as defined in claim 74), or a pharmaceutically acceptable salt thereof.
- 15 89. The fused ring compound of claim 88, wherein the Y is
 $-(CH_2)_m-O-(CH_2)_n-$ wherein each symbol is as defined in claim 74, or a pharmaceutically acceptable salt thereof.
90. The fused ring compound of claim 74, wherein the R² is
 20 carboxyl, R¹, R³ and R⁴ are hydrogen atoms, the ring Cy' is cyclopentyl, cyclohexyl or cycloheptyl, and the ring A' is phenyl, or a pharmaceutically acceptable salt thereof.
91. The fused ring compound of claim 42 or a pharmaceutically
 25 acceptable salt thereof, which is selected from the group consisting of
 ethyl 2-[4-(3-bromophenoxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate,
 2-[4-(3-bromophenoxy)phenyl]-1-cyclohexylbenzimidazole-5-
 30 carboxylic acid,
 ethyl 2-[4-(2-bromo-5-chlorobenzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate,
 ethyl 2-[4-[2-(4-chlorophenyl)-5-chlorobenzyloxy]phenyl]-1-cyclohexylbenzimidazole-5-carboxylate,
 35 2-[4-[2-(4-chlorophenyl)-5-chlorobenzyloxy]phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid,
 ethyl 2-[4-(2-bromo-5-methoxybenzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate,

ethyl 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylate,
 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
 5 ethyl 1-cyclohexyl-2-{4-[(E)-2-phenylvinyl]phenyl}benzimidazole-5-carboxylate,
 1-cyclohexyl-2-{4-[(E)-2-phenylvinyl]phenyl}benzimidazole-5-carboxylic acid,
 2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole-5-carboxylic
 10 acid,
 2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole-5-carboxamide,
 2-(4-benzyloxyphenyl)-5-cyano-1-cyclopentylbenzimidazole,
 2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole-5-carboxamide
 oxime,
 15 ethyl 1-cyclohexyl-2-{4-[{4-(4-fluorophenyl)-2-methyl-5-thiazolyl}methoxy]phenyl}benzimidazole-5-carboxylate,
 1-cyclohexyl-2-{4-[{4-(4-fluorophenyl)-2-methyl-5-thiazolyl}-methoxy]phenyl}benzimidazole-5-carboxylic acid,
 ethyl 2-{4-[bis(3-fluorophenyl)methoxy]-2-fluorophenyl}-1-
 20 cyclohexylbenzimidazole-5-carboxylate,
 2-{4-[bis(3-fluorophenyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
 ethyl 2-(4-benzoylaminophenyl)-1-cyclopentylbenzimidazole-5-carboxylate,
 25 2-(4-benzoylaminophenyl)-1-cyclopentylbenzimidazole-5-carboxylic acid,
 ethyl 2-{4-[3-(3-chlorophenyl)phenoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylate,
 2-{4-[3-(3-chlorophenyl)phenoxy]phenyl}-1-cyclohexyl-
 30 benzimidazole-5-carboxylic acid,
 ethyl 2-[4-(3-acetoxyphenyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate,
 ethyl 1-cyclohexyl-2-[4-(3-hydroxyphenyloxy)phenyl]-benzimidazole-5-carboxylate,
 35 ethyl 1-cyclohexyl-2-{4-[3-(4-pyridylmethoxy)phenyloxy]phenyl}-benzimidazole-5-carboxylate,
 1-cyclohexyl-2-{4-[3-(4-pyridylmethoxy)phenyloxy]phenyl}-benzimidazole-5-carboxylic acid,

- 2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole,
ethyl 2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole-5-
carboxylate,
2-(4-benzyloxyphenyl)-1-cyclopentyl-N,N-dimethylbenzimidazole-5-
5 carboxamide,
2-(4-benzyloxyphenyl)-1-cyclopentyl-N-methoxy-N-
methylbenzimidazole-5-carboxamide,
2-(4-benzyloxyphenyl)-1-cyclopentyl-5-(1-hydroxy-1-methylethyl)-
benzimidazole,
10 5-acetyl-2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole,
2-(4-benzyloxyphenyl)-1-cyclopentyl-N-(2-dimethylaminoethyl)-
benzimidazole-5-carboxamide dihydrochloride,
2-(4-benzyloxyphenyl)-1-cyclopentyl-5-nitrobenzimidazole,
5-amino-2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole
15 hydrochloride,
5-acetylamino-2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole,
2-(4-benzyloxyphenyl)-1-cyclopentyl-5-methanesulfonyl-
aminobenzimidazole,
5-sulfamoyl-2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazole,
20 2-[4-(4-tert-butylbenzyloxy)phenyl]-1-cyclopentylbenzimidazole-
5-carboxylic acid,
2-[4-(4-carboxybenzyloxy)phenyl]-1-cyclopentylbenzimidazole-5-
carboxylic acid,
2-[4-(4-chlorobenzyloxy)phenyl]-1-cyclopentylbenzimidazole-5-
25 carboxylic acid,
2-{4-[(2-chloro-5-thienyl)methoxy]phenyl}-1-cyclopentyl-
benzimidazole-5-carboxylic acid,
1-cyclopentyl-2-[4-(4-trifluoromethylbenzyloxy)phenyl]-
benzimidazole-5-carboxylic acid,
30 1-cyclopentyl-2-[4-(4-methoxybenzyloxy)phenyl]benzimidazole-5-
carboxylic acid,
1-cyclopentyl-2-[4-(4-pyridylmethoxy)phenyl]benzimidazole-5-
carboxylic acid hydrochloride,
1-cyclopentyl-2-[4-(4-methylbenzyloxy)phenyl]benzimidazole-5-
35 carboxylic acid,
1-cyclopentyl-2-{4-[(3,5-dimethyl-4-isoxazolyl)methoxy]phenyl}-
benzimidazole-5-carboxylic acid,

[2-(4-benzyloxyphenyl)-1-cyclopentylbenzimidazol-5-yl]-
 carbonylaminoacetic acid,
 2-[4-(2-chlorobenzyloxy)phenyl]-1-cyclopentylbenzimidazole-5-
 carboxylic acid,
 5 2-[4-(3-chlorobenzyloxy)phenyl]-1-cyclopentylbenzimidazole-5-
 carboxylic acid,
 2-(4-benzyloxyphenyl)-3-cyclopentylbenzimidazole-5-carboxylic
 acid,
 2-[4-(benzenesulfonylamino)phenyl]-1-cyclopentylbenzimidazole-5-
 10 carboxylic acid,
 1-cyclopentyl-2-[4-(3,5-dichlorophenylcarbonylamino)phenyl]-
 benzimidazole-5-carboxylic acid,
 2-[4-[(4-chlorophenyl)carbonylamino]phenyl]-1-cyclopentyl-
 benzimidazole-5-carboxylic acid,
 15 2-[4-[(4-tert-butylphenyl)carbonylamino]phenyl]-1-cyclopentyl-
 benzimidazole-5-carboxylic acid,
 2-[4-[(4-benzyloxyphenyl)carbonylamino]phenyl]-1-cyclopentyl-
 benzimidazole-5-carboxylic acid,
 trans-4-[2-(4-benzyloxyphenyl)-5-carboxybenzimidazol-1-
 20 yl]cyclohexan-1-ol,
 trans-1-[2-(4-benzyloxyphenyl)-5-carboxybenzimidazol-1-yl]-4-
 methoxycyclohexane,
 2-(4-benzyloxyphenyl)-5-carboxymethyl-1-cyclopentylbenzimidazole,
 2-[(4-cyclohexylphenyl)carbonylamino]-1-
 25 cyclopentylbenzimidazole-5-carboxylic acid,
 1-cyclopentyl-2-[4-(3,5-dichlorobenzyloxy)phenyl]benzimidazole-
 5-carboxylic acid,
 1-cyclopentyl-2-[4-(3,4-dichlorobenzyloxy)phenyl]benzimidazole-
 5-carboxylic acid,
 30 1-cyclopentyl-2-[4-(phenylcarbamoyleamino)phenyl]benzimidazole-5-
 carboxylic acid,
 1-cyclopentyl-2-[4-(diphenylmethoxy)phenyl]benzimidazole-5-
 carboxylic acid,
 1-cyclopentyl-2-(4-phenethyloxyphenyl)benzimidazole-5-carboxylic
 35 acid,
 trans-1-[2-(4-benzyloxyphenyl)-5-carboxybenzimidazol-1-yl]-4-
 tert-butylcyclohexane,

- 2-(4-benzyloxyphenyl)-5-carboxymethoxy-1-cyclopentylbenzimidazole,
- 2-(4-benzylaminophenyl)-1-cyclopentylbenzimidazole-5-carboxylic acid,
- 5 2-[4-(N-benzenesulfonyl-N-methylamino)phenyl]-1-cyclopentylbenzimidazole-5-carboxylic acid,
- 2-[4-(N-benzyl-N-methylamino)phenyl]-1-cyclopentylbenzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-(4-phenethylphenyl)benzimidazole-5-carboxylic acid,
- 10 1-cyclohexyl-2-[4-(3,5-dichlorobenzyloxy)phenyl]benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-[4-(diphenylmethoxy)phenyl]benzimidazole-5-carboxylic acid,
- 15 1-cyclohexyl-2-[4-(3,5-di-tert-butylbenzyloxy)phenyl]benzimidazole-5-carboxylic acid,
- 2-(4-benzyloxyphenyl)-1-(4-methylcyclohexyl)benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-[4-[2-(2-naphthyl)ethoxy]phenyl]benzimidazole-5-carboxylic acid,
- 20 1-cyclohexyl-2-[4-(1-naphthyl)methoxyphenyl]benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-[4-(dibenzylamino)phenyl]benzimidazole-5-carboxylic acid,
- 25 2-[4-(2-biphenylmethoxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-(4-benzyloxyphenyl)-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-[4-(dibenzylmethoxy)phenyl]benzimidazole-5-carboxylic acid,
- 30 2-(4-benzoylmethoxyphenyl)-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-[4-(3,3-diphenylpropyloxy)phenyl]benzimidazole-5-carboxylic acid,
- 35 2-[4-(3-chloro-6-phenylbenzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-[4-[2-(phenoxy)ethoxy]phenyl]benzimidazole-5-carboxylic acid,

- 1-cyclohexyl-2-[4-(3-phenylpropyloxy)phenyl]benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-[4-(5-phenylpentyloxy)phenyl]benzimidazole-5-carboxylic acid,
- 5 2-(2-benzyloxy-5-pyridyl)-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-[4-[2-(3,4,5-trimethoxyphenyl)ethoxy]phenyl]-benzimidazole-5-carboxylic acid,
- 2-(4-benzyloxyphenyl)-1-(4,4-dimethylcyclohexyl)benzimidazole-5-
- 10 carboxylic acid,
- 1-cyclohexyl-2-[4-[2-(1-naphthyl)ethoxy]phenyl]benzimidazole-5-carboxylic acid,
- 2-[4-(2-benzyloxyphenoxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 15 2-[4-(3-benzyloxyphenoxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-[4-(2-hydroxyphenoxy)phenyl]benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-[4-(3-hydroxyphenoxy)phenyl]benzimidazole-5-
- 20 carboxylic acid,
- 1-cyclohexyl-2-[4-(2-methoxyphenoxy)phenyl]benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-[4-(3-methoxyphenoxy)phenyl]benzimidazole-5-carboxylic acid,
- 25 1-cyclohexyl-2-[4-(2-propoxyphenoxy)phenyl]benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-[4-(3-propoxyphenoxy)phenyl]benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-[4-[2-(3-methyl-2-butenyloxy)phenoxy]phenyl]-
- 30 benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-[4-[3-(3-methyl-2-butenyloxy)phenoxy]phenyl]-benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-[4-(2-isopentyloxyphenoxy)phenyl]benzimidazole-5-carboxylic acid,
- 35 1-cyclohexyl-2-[4-(3-isopentyloxyphenoxy)phenyl]benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-[4-[2-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)ethoxy]phenyl]benzimidazole-5-carboxylic acid,

- 1-cyclohexyl-2-{4-[2-(4-trifluoromethylphenyl)benzyloxy]-phenyl}benzimidazole-5-carboxylic acid,
- 2-{4-[bis(4-chlorophenyl)methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 5 1-cyclohexyl-2-{4-[2-(4-methoxyphenyl)ethoxy]phenyl}-benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-{4-[2-(2-methoxyphenyl)ethoxy]phenyl}-benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-{4-[2-(3-methoxyphenyl)ethoxy]phenyl}-
- 10 benzimidazole-5-carboxylic acid,
- 2-(4-benzyloxyphenyl)-1-cycloheptylbenzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-[4-(2-phenethyloxyphenoxy)phenyl]benzimidazole-5-carboxylic acid,
- 15 1-cyclohexyl-2-[4-(3-phenethyloxyphenoxy)phenyl]benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-[4-(2,2-diphenylethoxy)phenyl]benzimidazole-5-carboxylic acid,
- cis-1-[2-(4-benzyloxyphenyl)-5-carboxybenzimidazol-1-yl]-4-
- 20 fluorocyclohexane,
- 1-cyclohexyl-2-[4-(2-phenoxyphenoxy)phenyl]benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-[4-(3-phenoxyphenoxy)phenyl]benzimidazole-5-carboxylic acid,
- 25 2-{4-[(2R)-2-benzyloxycarbonylamino-2-phenylethoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-{2-fluoro-4-[2-(4-trifluoromethylphenyl)-benzyloxy]phenyl}benzimidazole-5-carboxylic acid,
- 2-[4-(4-benzyloxyphenoxy)phenyl]-1-cyclohexylbenzimidazole-5-
- 30 carboxylic acid,
- 2-{4-[bis(4-methylphenyl)methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[bis(4-fluorophenyl)methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 35 1-cyclohexyl-6-methoxy-2-[4-(3-phenylpropoxy)phenyl]-benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-6-hydroxy-2-[4-(3-phenylpropoxy)phenyl]-benzimidazole-5-carboxylic acid,

- 1-cyclohexyl-6-methyl-2-[4-(3-phenylpropoxy)phenyl]-
benzimidazole-5-carboxylic acid,
- 2-[4-[2-(2-benzyloxyphenyl)ethoxy]phenyl]-1-cyclohexyl-
benzimidazole-5-carboxylic acid,
- 5 2-[4-[2-(3-benzyloxyphenyl)ethoxy]phenyl]-1-cyclohexyl-
benzimidazole-5-carboxylic acid,
- 2-[4-(2-carboxymethyloxyphenoxy)phenyl]-1-cyclohexyl-
benzimidazole-5-carboxylic acid,
- 2-[4-(3-carboxymethyloxyphenoxy)phenyl]-1-cyclohexyl-
10 benzimidazole-5-carboxylic acid,
- 2-[4-[3-chloro-6-(4-methylphenyl)benzyloxy]phenyl]-1-cyclohexyl-
benzimidazole-5-carboxylic acid,
- 2-[4-[3-chloro-6-(4-methoxyphenyl)benzyloxy]phenyl]-1-cyclohexyl-
benzimidazole-5-carboxylic acid,
- 15 1-cyclohexyl-2-[2-methyl-4-[2-(4-trifluoromethylphenyl)-
benzyloxy]phenyl]benzimidazole-5-carboxylic acid,
- 2-[4-[2-(4-tert-butylphenyl)-5-chlorobenzyloxy]phenyl]-1-
cyclohexylbenzimidazole-5-carboxylic acid,
- 2-[4-(3-chloro-6-phenylbenzyloxy)-2-fluorophenyl]-1-cyclohexyl-
20 benzimidazole-5-carboxylic acid,
- 2-[4-[3-chloro-6-(3,5-dichlorophenyl)benzyloxy]phenyl]-1-
cyclohexylbenzimidazole-5-carboxylic acid,
- 2-[4-[bis(4-fluorophenyl)methoxy]-2-fluorophenyl]-1-cyclohexyl-
benzimidazole-5-carboxylic acid,
- 25 2-[4-(4-benzyloxyphenoxy)-2-chlorophenyl]-1-cyclohexyl-
benzimidazole-5-carboxylic acid,
- 2-[4-(4-benzyloxyphenoxy)-2-trifluoromethylphenyl]-1-
cyclohexylbenzimidazole-5-carboxylic acid,
- 2-[4-[3-chloro-6-(2-trifluoromethylphenyl)benzyloxy]phenyl]-1-
30 cyclohexylbenzimidazole-5-carboxylic acid,
- 2-[4-[(2R)-2-amino-2-phenylethoxy]phenyl]-1-cyclohexyl-
benzimidazole-5-carboxylic acid,
- 2-[4-(2-biphenyloxy)phenyl]-1-cyclohexylbenzimidazole-5-
carboxylic acid,
- 35 2-[4-(3-biphenyloxy)phenyl]-1-cyclohexylbenzimidazole-5-
carboxylic acid,
- 2-[4-[2-[(1-tert-butoxycarbonyl-4-piperidyl)methoxy]phenoxy]-
phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid,

- 2-{4-[3-{(1-tert-butoxycarbonyl-4-piperidyl)methoxy}phenoxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[3-chloro-6-(3,4,5-trimethoxyphenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 5 2-{4-[2-(2-biphenyl)ethoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-[4-(2-biphenyl)methoxy]phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-{4-[2-(4-piperidylmethoxy)phenoxy]phenyl}-benzimidazole-5-carboxylic acid hydrochloride,
- 10 1-cyclohexyl-2-{4-[3-(4-piperidylmethoxy)phenoxy]phenyl}-benzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[(2R)-2-acetylamino-2-phenylethoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 15 1-cyclohexyl-2-{4-[3-(4-methyl-3-pentenyl)phenoxy]phenyl}-benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-{4-[3-(3-methyl-3-butenyl)phenoxy]phenyl}-benzimidazole-5-carboxylic acid,
- 2-{4-[(2S)-1-benzyl-2-pyrrolidinyl]methoxy}phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 20 2-{4-[3-chloro-6-(4-methylthiophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[3-chloro-6-(4-methanesulfonylphenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 25 2-{4-[3-chloro-6-(2-thienyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[3-chloro-6-(3-chlorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[3-chloro-6-(3-pyridyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 30 2-{4-[3-chloro-6-(4-fluorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-[4-(4-benzyloxyphenoxy)-3-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 35 2-[4-(2-bromo-5-chlorobenzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[3-chloro-6-(4-chlorophenyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,

- 2-{4-[2-{(1-acetyl-4-piperidyl)methoxy}phenoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[3-{(1-acetyl-4-piperidyl)methoxy}phenoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 5 1-cyclohexyl-2-{4-[3-(2-propynyloxy)phenoxy]phenyl}benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-{4-[3-(3-pyridylmethoxy)phenoxy]phenyl}benzimidazole-5-carboxylic acid,
- 2-(4-benzyloxy-2-methoxyphenyl)-1-cyclohexylbenzimidazole-5-
- 10 carboxylic acid,
- 2-[4-(2-bromo-5-methoxybenzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-[4-(carboxydiphenylmethoxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 15 2-{4-[2-(4-chlorophenyl)-5-nitrobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[3-acetylamino-6-(4-chlorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[2-(4-carboxyphenyl)-5-chlorobenzyloxy]phenyl}-1-
- 20 cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[(2S)-1-benzyloxycarbonyl-2-pyrrolidinyl]methoxy}phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{2-chloro-4-[2-(4-trifluoromethylphenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 25 1-cyclohexyl-2-{4-[3-(2-pyridylmethoxy)phenoxy]phenyl}benzimidazole-5-carboxylic acid,
- 2-{4-[2-(4-chlorophenyl)-5-fluorobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[3-carboxy-6-(4-chlorophenyl)benzyloxy]phenyl}-1-cyclohexyl-
- 30 benzimidazole-5-carboxylic acid,
- 2-{4-[3-carbamoyl-6-(4-chlorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-{4-[2-(dimethylcarbamoylmethoxy)phenoxy]phenyl}benzimidazole-5-carboxylic acid,
- 35 1-cyclohexyl-2-{4-[2-(piperidinocarbonylmethoxy)phenoxy]phenyl}benzimidazole-5-carboxylic acid,
- 2-{4-[(2S)-1-benzenesulfonyl-2-pyrrolidinyl]methoxy}phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,

- 2-{4-[(2S)-1-benzoyl-2-pyrrolidinylmethoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[2-(4-carbamoylphenyl)-5-chlorobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 5 1-cyclohexyl-2-{4-[3-(dimethylcarbamoylmethoxy)phenoxy]phenyl}-benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-{4-[3-(piperidinocarbonylmethoxy)phenoxy]phenyl}-benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-{4-[3-(1-methanesulfonyl-4-piperidyl)methoxy]phenoxy}phenylbenzimidazole-5-carboxylic acid,
- 10 1-cyclohexyl-2-{4-[(2-methyl-5-(4-chlorophenyl)-4-oxazolyl)methoxy]phenyl}benzimidazole-5-carboxylic acid,
- 2-{4-[3-(3-chlorobenzyloxy)phenoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 15 2-{4-[3-(4-chlorobenzyloxy)phenoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-{4-[3-(4-fluorobenzyloxy)phenoxy]phenyl}-benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-{4-[(2S)-1-(4-nitrophenyl)-2-pyrrolidinylmethoxy]phenyl}benzimidazole-5-carboxylic acid,
- 20 1-cyclohexyl-2-{4-[(2S)-1-phenyl-2-pyrrolidinylmethoxy]phenyl}-benzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[(2S)-1-(4-acetylamino-phenyl)-2-pyrrolidinylmethoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 25 2-{4-[(5-(4-chlorophenyl)-2-methyl-4-thiazolyl)methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[bis(3-fluorophenyl)methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-{4-[2-(4-chlorophenyl)-3-nitrobenzyloxy]phenyl}-benzimidazole-5-carboxylic acid,
- 30 1-cyclohexyl-2-{4-[3-(4-tetrahydropyranyloxy)phenoxy]phenyl}-benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-{4-[3-(4-trifluoromethylbenzyloxy)phenoxy]phenyl}-benzimidazole-5-carboxylic acid,
- 35 1-cyclohexyl-2-{4-[3-(1-methyl-4-piperidyl)methoxy]phenoxy}phenylbenzimidazole-5-carboxylic acid,
- 2-{4-[3-(4-tert-butylbenzyloxy)phenoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,

- 2-{4-[3-(2-chlorobenzyloxy)phenoxy]phenyl}-1-cyclohexyl-
benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-{4-[3-(3-pyridyl)phenoxy]phenyl}benzimidazole-5-
carboxylic acid,
- 5 2-{4-[3-(4-chlorophenyl)phenoxy]phenyl}-1-cyclohexyl-
benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-{4-[3-(4-methoxyphenyl)phenoxy]phenyl}-
benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-{4-[4-(4-methanesulfonylphenyl)-2-methyl-5-
10 thiazolyl]methoxy}phenyl}benzimidazole-5-carboxylic acid,
- 2-{4-[4-(4-chlorophenyl)-2-methyl-5-thiazolyl]methoxy}phenyl}-1-
cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[1-(4-chlorobenzyl)-3-piperidyloxy]phenyl}-1-cyclohexyl-
benzimidazole-5-carboxylic acid,
- 15 1-cyclohexyl-2-{4-[3-{(2-methyl-4-thiazolyl)methoxy}phenoxy]-
phenyl}benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-{4-[3-{(2,4-dimethyl-5-thiazolyl)methoxy}phenoxy]-
phenyl}benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-{4-[3-(3,5-dichlorophenyl)phenoxy]phenyl}-
20 benzimidazole-5-carboxylic acid,
- 2-{4-[1-(4-chlorobenzyl)-4-piperidyloxy]phenyl}-1-cyclohexyl-
benzimidazole-5-carboxylic acid,
- 2-{4-[3-(4-chlorobenzyloxy)piperidino]phenyl}-1-cyclohexyl-
benzimidazole-5-carboxylic acid,
- 25 2-{4-[4-carbamoyl-2-(4-chlorophenyl)benzyloxy]phenyl}-1-
cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[4-(4-chlorobenzyloxy)piperidino]phenyl}-1-cyclohexyl-
benzimidazole-5-carboxylic acid,
- 2-{4-[3-{(2-chloro-4-pyridyl)methoxy}phenoxy]phenyl}-1-
30 cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[{(2S)-1-(4-dimethylcarbamoylphenyl)-2-pyrrolidinyl}-
methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[2-(4-chlorophenyl)-5-ethoxycarbonylbenzyloxy]phenyl}-1-
cyclohexylbenzimidazole-5-carboxylic acid,
- 35 1-cyclohexyl-2-[4-(3-trifluoromethylphenoxy)phenyl]-
benzimidazole-5-carboxylic acid,
- 1-cyclohexyl-2-{4-[4-(4-dimethylcarbamoylphenyl)-2-methyl-5-
thiazolyl]methoxy}phenyl}benzimidazole-5-carboxylic acid,

2-[4-[2-(4-chlorophenyl)-5-dimethylcarbamoylbenzyloxy]phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid,

2-[4-[4-(4-chlorophenyl)-2-methyl-5-pyrimidinyl]methoxy]phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

5 2-[4-[2-(4-chlorophenyl)-3-pyridyl]methoxy]phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride,

2-[4-[3-(4-chlorophenyl)-2-pyridyl]methoxy]phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid,

2-[4-[2-(3-chlorophenyl)-4-methylamino-1,3,5-triazin-6-yloxy]phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid

10 trifluoroacetate,

2-[4-[2-(4-chlorophenyl)-4-(5-tetrazolyl)benzyloxy]phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid,

2-[4-(4-benzyloxy-6-pyrimidinyl)phenyl]-1-cyclohexyl-

15 benzimidazole-5-carboxylic acid,

1-cyclohexyl-2-[4-[4-(4-pyridylmethoxy)-6-pyrimidinyl]phenyl]-benzimidazole-5-carboxylic acid,

2-[4-[4-(3-chlorophenyl)-6-pyrimidinyl]phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid,

20 methyl 2-[4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl]-1-cyclohexylbenzimidazole-5-carboxylate,

2-[4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

ethyl 2-[4-[3-(4-chlorophenyl)pyridin-2-ylmethoxy]phenyl]-1-

25 cyclohexylbenzimidazole-5-carboxylate,

methyl 2-[4-(2-bromo-5-tert-butoxycarbonylbenzyloxy)phenyl]-1-cyclohexylbenzimidazole-5-carboxylate,

methyl 2-[4-[5-tert-butoxycarbonyl-2-(4-chlorophenyl)benzyloxy]phenyl]-1-cyclohexylbenzimidazole-5-carboxylate,

30 methyl 2-[4-[5-carboxy-2-(4-chlorophenyl)benzyloxy]phenyl]-1-cyclohexylbenzimidazole-5-carboxylate hydrochloride,

methyl 2-[4-[2-(4-chlorophenyl)-5-methylcarbamoylbenzyloxy]phenyl]-1-cyclohexylbenzimidazole-5-carboxylate,

2-[4-[2-(4-chlorophenyl)-5-methylcarbamoylbenzyloxy]phenyl]-1-

35 cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-[4-[3-(tert-butylsulfamoyl)-6-(4-chlorophenyl)benzyloxy]phenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid,

2-{4-[2-(4-chlorophenyl)-5-sulfamoylbenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid trifluoroacetate,
 2-(4-benzyloxycyclohexyl)-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

5 2-[2-(2-biphenylyloxymethyl)-5-thienyl]-1-cyclohexylbenzimidazole-5-carboxylic acid,
 2-[2-(2-biphenylyloxymethyl)-5-furyl]-1-cyclohexylbenzimidazole-5-carboxylic acid,
 1-cyclohexyl-2-{4-[4-(4-fluorophenyl)-2-hydroxymethyl-5-thiazolyl]methoxy}phenyl}benzimidazole-5-carboxylic acid,

10 1-cyclohexyl-2-{4-[4-(4-carboxyphenyl)-2-methyl-5-thiazolyl]methoxy}phenyl}benzimidazole-5-carboxylic acid hydrochloride,
 1-cyclohexyl-2-{2-fluoro-4-[4-fluoro-2-(3-fluorobenzoyl)-benzyloxy]phenyl}benzimidazole-5-carboxylic acid,

15 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-sulfonic acid,
 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-3-cyclohexylbenzimidazole-4-carboxylic acid,
 1-cyclohexyl-2-{4-[3-dimethylcarbamoyl-5-(4-pyridylmethoxy)-phenoxy]phenyl}benzimidazole-5-carboxylic acid dihydrochloride,

20 1-cyclohexyl-2-{4-[3-carboxy-5-(4-pyridylmethoxy)phenoxy]phenyl}benzimidazole-5-carboxylic acid dihydrochloride,
 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexylbenzimidazole-4-carboxylic acid,

25 2-{4-[3-carbamoyl-6-(4-chlorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
 2-{4-[2-(4-carboxyphenyl)-3-pyridyl]methoxy}phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-(4-tetrahydrothiopyranyl)benzimidazole-5-carboxylic acid,

30 2-{4-[2-(4-chlorophenyl)-5-dimethylcarbamoylbenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
 1-cyclohexyl-2-{4-[3-dimethylcarbamoyl-6-(4-trifluoromethylphenyl)benzyloxy]phenyl}benzimidazole-5-carboxylic acid hydrochloride,

35 1-cyclohexyl-2-{4-[3-dimethylcarbamoyl-6-(4-methylthiophenyl)-benzyloxy]phenyl}benzimidazole-5-carboxylic acid hydrochloride,

- 2-{4-[2-(4-chlorophenyl)-5-methylcarbamoylbenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-dimethylcarbamoylbenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[3-carbamoyl-6-(4-chlorophenyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[3-dimethylcarbamoyl-6-(4-methanesulfonylphenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[3-dimethylcarbamoyl-6-(3-pyridyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride,
- 2-{4-[3-dimethylcarbamoyl-6-(4-dimethylcarbamoylphenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]-2-fluorophenyl}-1-(4-tetrahydrothiopyranyl)benzimidazole-5-carboxylic acid,
- 2-{4-[2-(4-chlorophenyl)-5-dimethylsulfamoylbenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-methanesulfonylbenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- methyl 2-{4-[5-carboxy-2-(4-chlorophenyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylate hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-dimethylaminobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-methanesulfonylaminobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-diethylcarbamoylbenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-isopropylcarbamoylbenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-piperidinocarbonylbenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

- 2-{4-[2-(4-chlorophenyl)-5-(1-pyrrolidinyl)carbonylbenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(2-hydroxyethyl)carbamoylbenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(4-hydroxypiperidino)-carbonylbenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-morpholinocarbonylbenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-thiomorpholinocarbonylbenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[3-(carboxymethylcarbamoyl)-6-(4-chlorophenyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-{4-(2-carboxyethyl)phenyl}-5-chlorobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[3-chloro-6-(4-hydroxymethylphenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[3-chloro-6-(4-methoxymethylphenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(3-carboxyphenyl)-5-chlorobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[2-(4-chlorophenyl)-5-methylthiobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[2-(4-chlorophenyl)-5-methylsulfinylbenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[2-(4-chlorophenyl)-5-cyanobenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[bis(3-pyridyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[bis(4-dimethylcarbamoylphenyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- sodium 2-{4-[2-thienyl-3-thienylmethoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylate,

methyl 2-{4-[2-(4-chlorophenyl)-5-(dimethylcarbamoyl)benzyloxy]-
 2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylate,
 sodium 2-{4-[2-(4-chlorophenyl)-5-(dimethylcarbamoyl)benzyloxy]-
 2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylate,
 5 2-{4-[5-carboxy-2-(4-chlorophenyl)benzyloxy]-2-fluorophenyl}-1-
 cyclohexylbenzimidazole-5-carboxylic acid,
 2-{4-[2-(4-carboxyphenyl)-5-methoxybenzyloxy]phenyl}-1-
 cyclohexylbenzimidazole-5-carboxylic acid,
 2-{4-[2-(4-carbamoylphenyl)-5-(dimethylcarbamoyl)benzyloxy]-
 10 phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
 2-{4-[5-amino-2-(4-chlorophenyl)benzyloxy]phenyl}-1-cyclohexyl-
 benzimidazole-5-carboxylic acid,
 2-{4-[5-(4-chlorophenyl)-2-methoxybenzylsulfinyl]phenyl}-1-
 cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
 15 2-{4-[5-(4-chlorophenyl)-2-methoxybenzylsulfonyl]phenyl}-1-
 cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
 2-{4-[2-(4-chlorophenyl)-5-methoxybenzylthio]phenyl}-1-
 cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
 2-{4-[bis(4-carboxyphenyl)methoxy]-2-fluorophenyl}-1-
 20 cyclohexylbenzimidazole-5-carboxylic acid,
 2-[4-(phenyl-3-pyridylmethoxy)-2-fluorophenyl]-1-cyclohexyl-
 benzimidazole-5-carboxylic acid,
 methyl 2-{4-[2-(4-chlorophenyl)-5-(methylcarbamoyl)benzyloxy]-2-
 fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylate,
 25 2-{4-[5-chloro-2-(4-pyridyl)benzyloxy]-2-fluorophenyl}-1-
 cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
 2-{4-[2-(4-chlorophenyl)-5-(benzylcarbamoyl)benzyloxy]-2-
 fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid
 hydrochloride,
 30 2-{4-[2-(4-chlorophenyl)-5-(cyclohexylmethylcarbamoyl)benzyloxy]-
 2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid
 hydrochloride,
 2-{4-[2-(4-chlorophenyl)-5-(4-pyridylmethylcarbamoyl)benzyloxy]-
 2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid
 35 dihydrochloride,
 2-{4-[2-(4-chlorophenyl)-5-(N-benzyl-N-methylcarbamoyl)-
 benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic
 acid hydrochloride,

methyl 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexyl-1H-indole-5-carboxylate,
 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-1-cyclohexyl-1H-indole-5-carboxylic acid,
 5 2-(4-benzyloxyphenyl)-1-cyclopentyl-1H-indole-5-carboxylic acid,
 ethyl 2-(4-benzyloxyphenyl)-3-cyclohexylimidazo[1,2-a]pyridine-7-carboxylate,
 2-(4-benzyloxyphenyl)-3-cyclohexylimidazo[1,2-a]pyridine-7-carboxylic acid, and
 10 2-{4-[2-(4-chlorophenyl)-5-methoxybenzyloxy]phenyl}-3-cyclohexyl-3H-imidazo[4,5-b]pyridine-6-carboxylic acid.

92. The fused ring compound of claim 42 or a pharmaceutically acceptable salt thereof, which is selected from the group
 15 consisting of

2-{4-[5-dimethylaminocarbonyl-2-(4-pyridyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride,
 2-{4-[2-(4-chlorophenyl)-5-(4-methylpiperazin-1-ylcarbonyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-
 20 carboxylic acid dihydrochloride,
 2-{4-[2-(4-chlorophenyl)-5-{N-(3-pyridylmethyl)carbamoyl}benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride,
 2-{4-[2-(4-chlorophenyl)-5-{N-(2-pyridylmethyl)carbamoyl}benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid
 25 dihydrochloride,
 2-{4-[2-(4-chlorophenyl)-5-(cyclohexylcarbamoyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
 2-{4-[2-(4-chlorophenyl)-5-(2-pyridin-4-ylethylcarbamoyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid
 30 dihydrochloride,
 2-{4-[(4-fluorophenyl){4-(dimethylaminocarbonyl)phenyl}methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
 2-{4-[(4-fluorophenyl)(4-carboxyphenyl)methoxy]-2-fluorophenyl}-
 35 1-cyclohexylbenzimidazole-5-carboxylic acid,
 2-{4-[2-(4-chlorophenyl)-5-(4-oxopiperidinocarbonyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

- 2-{4-[2-(4-chlorophenyl)-5-hydroxybenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
 2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
 5 2-{4-[2-(4-chlorophenyl)-5-(N-isopropyl-N-methylcarbamoyl)-benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
 2-{4-[2-(4-chlorophenyl)-5-(phenylcarbamoyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
 10 2-{4-[2-(4-chlorophenyl)-5-(4-methoxypiperidinocarbonyl)-benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
 2-{4-[2-(4-chlorophenyl)-5-(3-hydroxypropyloxy)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid, and
 15 2-{4-[2-(4-chlorophenyl)-5-(2-hydroxyethoxy)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride.

93. The fused ring compound of claim 42 or a pharmaceutically acceptable salt thereof, which is selected from the group
 20 consisting of

- methyl 2-[4-(2-bromo-5-nitrobenzyloxy)-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate,
 methyl 2-[4-{2-(4-chlorophenyl)-5-nitrobenzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate,
 25 methyl 2-[4-{5-amino-2-(4-chlorophenyl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate,
 methyl 2-[4-{2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylate,
 30 2-[4-{2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy}-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
 2-{4-[2-(4-chlorophenyl)-5-(4-methylpiperidin-1-ylcarbonyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
 35 2-{4-[5-acetyl-2-(4-chlorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

- 2-{4-[2-(4-chlorophenyl)-5-{(4-hydroxypiperidin-1-ylcarbonyl)methoxy}benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[2-(4-chlorophenyl)-5-(2-methoxyethoxy)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-{2-(2-methoxyethoxy)ethoxy}benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(isobutylcarbonyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[2-(4-chlorophenyl)-5-(2-methylthiazol-4-yl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[2-(4-chlorophenyl)-5-(3,4-dihydroxypiperidin-1-ylcarbonyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(3-methyl-1,2,4-oxadiazol-5-yl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-4-(isopropylcarbamoyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-4-(piperidinocarbonyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-{(1-hydroxy-2-methylpropan-2-yl)carbamoyl}benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(4,4-dimethyl-2-oxazolin-2-yl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride,
- 2-{4-[2-(4-chlorophenyl)-4-(4-hydroxypiperidin-1-ylcarbonyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-4-{(2-hydroxyethyl)carbamoyl}benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-4-{(4-pyridylmethyl)carbamoyl}benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[2-(4-chlorophenyl)-4-(dimethylcarbamoyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[5-(2-aminothiazol-4-yl)-2-(4-chlorophenyl)benzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride,

2-{4-[2-(4-chlorophenyl)-5-(4-hydroxypiperidin-1-ylsulfonyl)-benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[5-(dimethylcarbamoyl)-2-(4-fluorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[5-(dimethylcarbamoyl)-2-(3-fluorophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[2-(5-chlorothiophen-2-yl)-5-(dimethylcarbamoyl)benzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[2-bromo-5-(5-methyloxazol-2-yl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[2-bromo-5-(5-methylthiazol-2-yl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[2-(4-chlorophenyl)-5-(5-methyloxazol-2-yl)benzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[2-(4-chlorophenyl)-5-(5-methylthiazol-2-yl)benzyloxy]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[2-(4-chlorophenyl)-5-tetrazol-5-ylbenzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[5-chloro-2-(4-cyanophenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[5-chloro-2-(4-tetrazol-5-ylphenyl)benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[2-(4-chlorophenyl)-5-{2-(4-hydroxypiperidin-1-yl)ethoxy}benzyloxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[2-(4-chlorophenyl)-5-(2-oxopiperidin-1-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[3-(4-chlorophenyl)-5-(dimethylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[2-(4-chlorophenyl)-5-(N-hydroxyamidino)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride,

2-{4-[2-(4-chlorophenyl)-5-(2,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[2-(4-chlorophenyl)-5-(2-oxo-3H-1,2,3,5-oxathiadiazol-4-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[2-(4-chlorophenyl)-5-(2,5-dihydro-5-oxo-4H-1,2,4-thiadiazol-3-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[2-(4-chlorophenyl)-5-(cyclopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[2-(4-chlorophenyl)-5-(cyclobutylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[2-(4-chlorophenyl)-5-(tert-butylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[2-(4-chlorophenyl)-5-(isobutylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[2-(4-chlorophenyl)-5-[(1-hydroxypropan-2-yl)carbamoyl]benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[2-(4-chlorophenyl)-5-(methoxycarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[2-(4-chlorophenyl)-5-[(2,3-dihydroxypropyl)carbamoyl]benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[2-(4-chlorophenyl)-5-(N-ethyl-N-methylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

2-{4-[2-(4-chlorophenyl)-5-(N-methyl-N-propylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

- 2-{4-[2-(4-chlorophenyl)-5-(N-isopropyl-N-methylcarbamoyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(2,6-dimethylpiperidin-1-ylcarbonyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[5-(butylcarbamoyl)-2-(4-chlorophenyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(propylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(ethylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-{(dimethylcarbamoyl)amino}benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-{(morpholinocarbonyl)amino}benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-ureidobenzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-{(ethylcarbamoyl)amino}benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-{(isopropylcarbamoyl)amino}benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(3,4-difluorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{4-[2-(2,4-difluorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(3,5-dichlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

- 2-{4-[2-(3-chloro-4-fluorophenyl)-5-(isopropylcarbamoyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(3,4-dichlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chloro-2-fluorophenyl)-5-(isopropylcarbamoyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chloro-2-fluorophenyl)-5-(pyrrolidin-1-ylcarbonyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chloro-3-fluorophenyl)-5-(pyrrolidin-1-ylcarbonyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chloro-3-fluorophenyl)-5-(isopropylcarbamoyl)-benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-{4-(methylthio)phenyl}-5-(2-oxopyrrolidin-1-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-{4-(methylthio)phenyl}-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[4-chloro-2-(4-chlorophenyl)-5-(1,1-dioxoisothiazolidin-2-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[4-chloro-2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(isopropylaminosulfonyl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(dimethylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid hydrochloride,

- 2-{4-[2-(4-chlorophenyl)-5-(4-hydroxypiperidin-1-ylcarbonyl)-benzyloxy]-2-fluorophenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]phenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(dimethylcarbamoyl)benzyloxy]phenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(4-hydroxypiperidin-1-ylcarbonyl)-benzyloxy]phenyl}-1-cyclopentylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]phenyl}-1-(tetrahydrothiopyran-4-yl)benzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(pyrrolidin-1-ylcarbonyl)benzyloxy]phenyl}-1-(tetrahydrothiopyran-4-yl)benzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-(tetrahydrothiopyran-4-yl)benzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzyloxy]-2-fluorophenyl}-1-(tetrahydrothiopyran-4-yl)benzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-piperidinobenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(pyrrolidin-1-ylcarbonyl)benzyloxy]-2-fluorophenyl}-1-piperidinobenzimidazole-5-carboxylic acid,
- 2-{4-[2-(4-chlorophenyl)-5-(2-imidazolin-2-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(2-oxooxazolidin-3-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,

- 2-{4-[2-(4-chlorophenyl)-5-(2-oxoimidazolidin-1-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(2-oxazolin-2-ylamino)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride,
- 2-{4-[2-[(dimethylcarbamoyl)methoxy]methyl]-4-(4-fluorophenyl)thiazol-5-yl}methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[4-(4-fluorophenyl)-2-(4-hydroxypiperidin-1-ylmethyl)thiazol-5-yl}methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid dihydrochloride,
- 2-{4-[4-(4-fluorophenyl)-2-[(carbamoylmethoxy)methyl]thiazol-5-yl}methoxy]phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[4-(4-fluorophenyl)-2-(methylcarbamoyl)thiazol-5-yl}methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[4-(4-fluorophenyl)-2-(2-hydroxyethyl)carbamoyl]thiazol-5-yl}methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-fluorophenyl)-5-(dimethylcarbamoyl)thiophen-3-yl}methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-fluorophenyl)-5-(isopropylcarbamoyl)thiophen-3-yl}methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-fluorophenyl)-5-(4-hydroxypiperidin-1-yl carbonyl)thiophen-3-yl}methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(dimethylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexyl-5-tetrazol-5-ylbenzimidazole,
- 2-{4-[2-(4-carboxyphenyl)-5-chlorobenzyloxy]-2-fluorophenyl}-1-cyclohexyl-5-tetrazol-5-ylbenzimidazole hydrochloride,
- 2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]-2-fluorophenyl}-1-cyclohexyl-5-(2,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl)benzimidazole hydrochloride,

- 2-{4-[5-carboxy-2-(4-chlorophenyl)benzyloxy]-2-fluorophenyl}-5-cyano-1-cyclohexylbenzimidazole,
- 2-{4-[2-(4-chlorophenyl)-5-(dimethylcarbamoyl)benzyloxy]-2-fluorophenyl}-5-cyano-1-cyclohexylbenzimidazole,
- 5 2-{4-[{N-(4-dimethylcarbamoyl)-N-(4-fluorophenyl)amino}methyl]-phenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{5-[bis(3-fluorophenyl)methyl]-2-fluoro-4-hydroxyphenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 2-{3-[bis(3-fluorophenyl)methyl]-2-fluoro-4-hydroxyphenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid,
- 10 2-{4-[(3-dimethylcarbamoylphenyl)(4-fluorophenyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 2-{4-[{3-(4-hydroxypiperidyl-1-ylcarbonyl)phenyl}(4-fluorophenyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 15 1-{[2-{4-([4-(4-fluorophenyl)-2-methylthiazol-5-yl]methoxy)phenyl}-1-cyclohexylbenzimidazol-5-yl]carbonyl}-β-D-glucuronic acid,
- 20 {[2-{4-[bis(3-fluorophenyl)methoxy]-2-fluorophenyl}-1-cyclohexylbenzimidazol-5-yl]carbonyl}-β-D-glucuronic acid,
- 2-{4-[2-(4-chlorophenyl)-5-(1,1-dioxoisothiazolidin-2-yl)benzyloxy]-2-fluorophenyl}-1-cyclohexylbenzimidazole-5-carboxylic acid hydrochloride,
- 25 2-{4-[2-(4-chlorophenyl)-5-(isopropylcarbamoyl)benzyloxy]phenyl}-3-cyclohexyl-3H-imidazo[4,5-b]pyridine-6-carboxylic acid hydrochloride, and
- 2-{4-[2-(4-chlorophenyl)-5-(pyrrolidin-1-ylcarbonyl)benzyloxy]phenyl}-3-cyclohexyl-3H-imidazo[4,5-b]pyridine-6-carboxylic acid
- 30 hydrochloride.

94. A pharmaceutical composition comprising a fused ring compound of claim 42, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

95. A hepatitis C virus polymerase inhibitor comprising a fused ring compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

96. An anti-hepatitis C virus agent comprising a fused ring compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

5

97. A therapeutic agent for hepatitis C comprising a fused ring compound of claim 42, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10 98. An anti-hepatitis C virus agent comprising (a) the anti-hepatitis C virus agent of claim 96 and (b) at least one agent selected from the group consisting of a different antiviral agent, an antiinflammatory agent and an immunostimulant.

15 99. An anti-hepatitis C virus agent comprising (a) the anti-hepatitis C virus agent of claim 96 and (b) interferon.

100. A therapeutic agent for hepatitis C comprising (a) the hepatitis C virus polymerase inhibitor of claim 95 and (b) at
20 least one agent selected from the group consisting of a different antiviral agent, an antiinflammatory agent and an immunostimulant.

101. A therapeutic agent for hepatitis C comprising (a) the hepatitis C virus polymerase inhibitor of claim 95 and (b)
25 interferon.

102. A thiazole compound selected from the group consisting of 4-(4-fluorophenyl)-5-hydroxymethyl-2-methylthiazole and 4-(4-fluorophenyl)-5-chloromethyl-2-methylthiazole, or a
30 pharmaceutically acceptable salt thereof.

103. A pharmaceutical composition comprising (a) the fused compound of the formula [I] of claim 1 or a pharmaceutically acceptable salt thereof and (b) at least one agent selected from
35 the group consisting of an antiviral agent other than the compound of claim 1, an antiinflammatory agent and an immunostimulant.

104. A pharmaceutical composition comprising (a) the fused compound of the formula [I] of claim 1 or a pharmaceutically acceptable salt thereof and (b) interferon.

5 105. A method for treating hepatitis C, which comprises administering an effective amount of a fused ring compound of the formula [I] of claim 1 or a pharmaceutically acceptable salt thereof.

10 106. The method of claim 105, further comprising administering an effective amount of at least one agent selected from the group consisting of an antiviral agent other than the compound of claim 1, an antiinflammatory agent and an immunostimulant.

15 107. The method of claim 105, further comprising administering an effective amount of interferon.

108. A method for inhibiting hepatitis C virus polymerase, which comprises administering an effective amount of a fused ring
20 compound of the formula [I] of claim 1 or a pharmaceutically acceptable salt thereof.

109. The method of claim 108, further comprising administering an effective amount of at least one agent selected from the group
25 consisting of an antiviral agent other than the compound of claim 1, an antiinflammatory agent and an immunostimulant.

110. The method of claim 108, further comprising administering an effective amount of interferon.

30